JPH0373525B2 - - Google Patents
Info
- Publication number
- JPH0373525B2 JPH0373525B2 JP22783682A JP22783682A JPH0373525B2 JP H0373525 B2 JPH0373525 B2 JP H0373525B2 JP 22783682 A JP22783682 A JP 22783682A JP 22783682 A JP22783682 A JP 22783682A JP H0373525 B2 JPH0373525 B2 JP H0373525B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- general formula
- compound
- sulfide
- oxazaphosphorine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 claims description 66
- -1 thio compound Chemical class 0.000 claims description 64
- 150000003839 salts Chemical class 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 8
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- ZZVDXRCAGGQFAK-UHFFFAOYSA-N 2h-oxazaphosphinine Chemical compound N1OC=CC=P1 ZZVDXRCAGGQFAK-UHFFFAOYSA-N 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 5
- 239000008024 pharmaceutical diluent Substances 0.000 claims 5
- 125000003277 amino group Chemical group 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 239000012059 conventional drug carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 78
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 62
- 235000018417 cysteine Nutrition 0.000 description 62
- 206010028980 Neoplasm Diseases 0.000 description 41
- 239000007924 injection Substances 0.000 description 33
- 238000002347 injection Methods 0.000 description 33
- 229940090044 injection Drugs 0.000 description 32
- 229960004397 cyclophosphamide Drugs 0.000 description 24
- 239000000243 solution Substances 0.000 description 24
- 241001465754 Metazoa Species 0.000 description 22
- 238000002512 chemotherapy Methods 0.000 description 22
- 201000011510 cancer Diseases 0.000 description 21
- 125000004149 thio group Chemical group *S* 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 239000007928 intraperitoneal injection Substances 0.000 description 12
- 230000010412 perfusion Effects 0.000 description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000007912 intraperitoneal administration Methods 0.000 description 10
- 238000001990 intravenous administration Methods 0.000 description 10
- 230000001988 toxicity Effects 0.000 description 10
- 231100000419 toxicity Toxicity 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 239000004201 L-cysteine Substances 0.000 description 8
- 235000013878 L-cysteine Nutrition 0.000 description 8
- 239000003708 ampul Substances 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 150000003946 cyclohexylamines Chemical class 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000000699 topical effect Effects 0.000 description 8
- 238000010253 intravenous injection Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000009897 systematic effect Effects 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 206010033128 Ovarian cancer Diseases 0.000 description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- 238000002513 implantation Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 229910021529 ammonia Inorganic materials 0.000 description 5
- 150000003863 ammonium salts Chemical class 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 125000000542 sulfonic acid group Chemical group 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 206010005003 Bladder cancer Diseases 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 206010017711 Gangrene Diseases 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 4
- 230000007059 acute toxicity Effects 0.000 description 4
- 231100000403 acute toxicity Toxicity 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 201000003146 cystitis Diseases 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 201000005112 urinary bladder cancer Diseases 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 3
- 238000011785 NMRI mouse Methods 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000000824 cytostatic agent Substances 0.000 description 3
- 230000001085 cytostatic effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 3
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 2
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 2
- RANONBLIHMVXAJ-UHFFFAOYSA-N 4-hydroxycyclophosphamide Chemical compound OC1CCOP(=O)(N(CCCl)CCCl)N1 RANONBLIHMVXAJ-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 2
- 206010027463 Metastases to pleura Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 102100024304 Protachykinin-1 Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 101800003906 Substance P Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002497 edematous effect Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000004964 sulfoalkyl group Chemical group 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 150000003460 sulfonic acids Chemical class 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 210000003741 urothelium Anatomy 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N βâMercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- BTMBBBJCNPAWHZ-UHFFFAOYSA-N 2,3-dihydrooxazaphosphinin-4-one Chemical compound O=C1PNOC=C1 BTMBBBJCNPAWHZ-UHFFFAOYSA-N 0.000 description 1
- BYUKOOOZTSTOOH-UHFFFAOYSA-N 2-(2-sulfoethyldisulfanyl)ethanesulfonic acid Chemical compound OS(=O)(=O)CCSSCCS(O)(=O)=O BYUKOOOZTSTOOH-UHFFFAOYSA-N 0.000 description 1
- UPRCYLSKSSRHMY-UHFFFAOYSA-N 2-(2h-oxazaphosphinin-4-ylsulfanyl)ethanol Chemical compound OCCSC1=PNOC=C1 UPRCYLSKSSRHMY-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- RGMAHYFJESFZQL-UHFFFAOYSA-N 2-[[3-(2-chloroethyl)-2-(2-chloroethylamino)-2-oxo-1,3,2$l^{5}-oxazaphosphinan-4-yl]sulfanyl]ethanol Chemical compound OCCSC1CCOP(=O)(NCCCl)N1CCCl RGMAHYFJESFZQL-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 229940006193 2-mercaptoethanesulfonic acid Drugs 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010051779 Bone marrow toxicity Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 201000005262 Chondroma Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 101000835998 Homo sapiens SRA stem-loop-interacting RNA-binding protein, mitochondrial Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101100332755 Mus musculus Edar gene Proteins 0.000 description 1
- LIMFPAAAIVQRRD-BCGVJQADSA-N N-[2-[(3S,4R)-3-fluoro-4-methoxypiperidin-1-yl]pyrimidin-4-yl]-8-[(2R,3S)-2-methyl-3-(methylsulfonylmethyl)azetidin-1-yl]-5-propan-2-ylisoquinolin-3-amine Chemical compound F[C@H]1CN(CC[C@H]1OC)C1=NC=CC(=N1)NC=1N=CC2=C(C=CC(=C2C=1)C(C)C)N1[C@@H]([C@H](C1)CS(=O)(=O)C)C LIMFPAAAIVQRRD-BCGVJQADSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100025491 SRA stem-loop-interacting RNA-binding protein, mitochondrial Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000009916 Yoshida Sarcoma Diseases 0.000 description 1
- ONSQLDCEJIIUJS-XVFCMESISA-N [(2r,3s,4r,5r)-5-(2-amino-4-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound NC1=NC(=O)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 ONSQLDCEJIIUJS-XVFCMESISA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000005236 alkanoylamino group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 231100000366 bone marrow toxicity Toxicity 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000007988 cartilage cancer Diseases 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- ZNEWHQLOPFWXOF-UHFFFAOYSA-N coenzyme M Chemical compound OS(=O)(=O)CCS ZNEWHQLOPFWXOF-UHFFFAOYSA-N 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 229940127108 compound 5g Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 229940048998 cysteine injection Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- WQABCVAJNWAXTE-UHFFFAOYSA-N dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YVKSGVDJQXLXDV-BYPYZUCNSA-N ethyl (2r)-2-amino-3-sulfanylpropanoate Chemical compound CCOC(=O)[C@@H](N)CS YVKSGVDJQXLXDV-BYPYZUCNSA-N 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 210000001595 mastoid Anatomy 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 229960001913 mecysteine Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000005358 mercaptoalkyl group Chemical group 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- MCYHPZGUONZRGO-VKHMYHEASA-N methyl L-cysteinate Chemical compound COC(=O)[C@@H](N)CS MCYHPZGUONZRGO-VKHMYHEASA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000003281 pleural cavity Anatomy 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- UWHMFGKZAYHMDJ-UHFFFAOYSA-N propane-1,2,3-trithiol Chemical compound SCC(S)CS UWHMFGKZAYHMDJ-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000007666 subchronic toxicity Effects 0.000 description 1
- 231100000195 subchronic toxicity Toxicity 0.000 description 1
- 150000008054 sulfonate salts Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
äžè¬åŒ
ãåŒäžãR5â²ã¯âïŒCH2ïŒoâOHãè¡šãããïœã¯
ïŒïŒïŒïŒïŒåã¯ïŒãè¡šãããã®ååç©ã¯å ¬ç¥ã§ã
ãããã®ååç©ã¯æè «çäœçšãæãããåæã«é
åžžã«æ¯æ§ã§ããïŒTetrahedron Letters第10å·»
ïŒ1979幎ïŒã第883ã886é ïŒCancer Chemother.
Pharmacol.第ïŒå·»ïŒ1979幎ïŒç¬¬181ã188é å
ç §ïŒã æŽã«ãã«ã³ãµâã»ããªâãã¡ã³ãã»ã¬ãâã
ïŒCanser Treatment ReportsïŒç¬¬60å·»ïŒ1976
幎ïŒã第355ã359é ã«ã¯ïŒâããããã·âã·ã¯ã
ãã¹ãã¢ãããšã·ã¹ãã€ã³ãâã¢ã»ãã«âã·ã¹
ãã€ã³åã³ã°ã«ã¿ããªã³ããã®äžè¬åŒ ãåŒäžãR5â³ã¯âCH2âCHïŒNH2ïŒâCO2å
ã¯âCH2âCHïŒNHCOCH3ïŒâCO2ãè¡šããã
ã®ååç©ã®è£œé ãèšèŒãããŠããã æ¬çºæã¯ç¹èš±è«æ±ã®ç¯å²ã«èšèŒããã課é¡ã«é¢
ããã äžè¬åŒã®ååç©ãšäžè¬åŒã®ååç©ã®æ¬çºæ
ã«ãã䜿çšã«ããäžè¬æ¯æ§ã®èããæžå°ãšåæã«
è¯å¥œãªç现èæ¯äœçšãéããããã®ã§ãæ¬çºæã«
ããçµåããã«ãã€ãŠççŸæ£ã®å±æååŠçæ³åã³
æé©ãªç³»çµ±çååŠçæ³ãå¯èœãšãªãã äžè¬åŒã®ååç©ã¯çš®ã ã®ç«äœç°æ§äœãäŸãã°
ã©ã»ãâããšããŠãå åŠæŽ»æ§ååç©ãšããŠåã¯ãž
ã¢ã¹ãã¬ãªãâïŒã·ã¹åã³ãã©ã³ã¹åïŒãšããŠå
åšãããäžè¬åŒã®ååç©ãšã¯ãã¹ãŠã®å¯èœãªç«
äœç°æ§ã®ååç©åã³ãããã®æ··åç©ãè¡šãããäž
è¬åŒã®ãã®ãããªååç©ã®è£œé ã¯äŸãã°ç¹é¡æ
57â44779å·æ现æžïŒè¥¿ãã€ãåœç¹èš±åºé¡
p3220432.9å·æ现æžãããã¯åp3111428.8å·æ现
æžïŒäžã«èšèŒããæ¹æ³ã«ããè¡ãªãããšãã§ã
ãã äžè¬åŒåã³äžè¬åŒã®ååç©ã«ãããããã
ãã·ã¢ã«ãã«åºãã¡ã«ã«ããã¢ã«ãã«åºã¯çŽéå
ã¯åæéã§ãã€ãŠãããããããã·åºãã¡ã«ã«ã
ãåºãã«ã«ããã·åºäžŠã³ã«ã¹ã«ãã³é žåºã¯ããã
ãã®ã¢ã«ãã«åºã®Ïäœã«ããã®ãæå©ã§ãããç¹
ã«ã¢ã«ãã«åºãšããŠã¯ççŽ ååæ°ïŒãïŒãç¹ã«ïŒ
ã®ãã®ãæå©ã§ãããåãããã«ãäžè¬åŒã®å
åç©ã®C2ãC6âã¢ã«ãã«åºã¯æå©ã«ççŽ ååæ°
ïŒãïŒã®ãã®ã§ãããäžè¬åŒã®R6ãC2ãC6â
ã¢ã«ã«ãã€ã«ã¢ããåºã«ãã眮æãããŠããC2
ãC6âã¢ã«ãã«åºãè¡šããå ŽåãC2ãC6âã¢ã«
ã«ãã€ã«ã¯äŸãã°ã¢ã»ãã«ãããããªãã«ããã
ãªã«ãã€ãœãããªã«ãtertâãããªã«ãè¡šããã R5ãã«ã«ãâC1ãC6âã¢ã«ã³ãã·âC1ãC10â
ã¢ã«ãã«åºãè¡šããå ŽåãC1ãC10âã¢ã«ãã«åº
ã¯æå©ã«ççŽ ååæ°ïŒãïŒã§ãããç¹ã«ççŽ åå
æ°ïŒïŒïŒïŒïŒïŒïŒåã¯ïŒã§ãããã«ã«ãâC1ã
C6âã¢ã«ã³ãã·åºã®æåãšããŠC1ãC6âã¢ã«ã³
ãã·åºã¯äžè¬ã«æå©ã«ççŽ ååæ°ïŒãïŒãæå©ã«
ççŽ ååïŒåã¯ïŒã§ããã äžè¬åŒã®åºR7ãC2ãC6âã¹ã«ãã¢ã«ãã«ã
ãªåºã§ããå Žåãäžè¬åŒHOâSO2âïœïœâ
ââïœïœâSO2âOHã®ãžããªâãžâC2ãC6
âã¢ã«ã«ã³ã¹ã«ãã³é žãè¡šãããããã§ã¯ïœïœ
ãšã¯ççŽ ååæ°ïŒãïŒã®çŽéåã¯åæéã¢ã«ãã¬
ã³åºã§ãããæå©ã«ïœïœã¯âCH2âCH2âã§ã
ãã C2ãC6âã¹ã«ãã¢ã«ãã«åºïŒäžè¬åŒã®åºR5ïŒ
ã«ååšããã¡ã«ã«ããåºã¯äŸãã°ã¢ã«ãã¬ã³éã®
ïŒâãïŒâãïŒâãïŒâåã¯ïŒâäœã®ççŽ åå
ïŒãã³ããªã³ã°ã¯ã¹ã«ãã³é žåºããéå§ããïŒã«
äœçœ®ãããããããªããã¡ã«ã«ããåºã¯ãªããµã¶
ãã¹ããªãã«âïŒïŒïŒâããªåºãšçµåããã¢ã«ãã¬
ã³éã®ççŽ ååã«ååšããªããŠãããã ç¹ã«ãåŒäžR5ãåèšã®ãã®ãè¡šãããåºR1ã
R4ã次ã®æå³ãæããååç©ãæå©ã§ããïŒ R1åã³R2ïŒïŒâã¯ãã«âãšãã«ãR3åã³R4
ïŒïŒšïŒ R1ãR2åã³R3ïŒïŒâã¯ãã«âãšãã«ãR4ïŒ
ïŒšïŒ R1åã³R3ïŒïŒâã¯ãã«âãšãã«ãR2åã³R4
ïŒïŒšã äžè¬åŒã®ããªååç©ãšããŠã¯ç¹ã«R7ãæ°ŽçŽ
ã§ããäžè¬åŒã®ååç©ãæããããšãã§ããã äžè¬åŒã®ååç©ãã¹ã«ãã³é žåºãæããå Ž
åããã®ã¹ã«ãã³é žåºãšå¡©ã圢æããããšã«ãã
çããäžè¬åŒã®ååç©ã®æ²»çäžäœ¿çšå¯èœãªå¡©ã
䜿çšããããšãã§ãããç¹ã«ããã®å Žåã¢ã«ã«ãª
éå±å¡©ïŒã«ãªãŠã ããããªãŠã ïŒãã¢ã«ã«ãªåé¡
éå±å¡©ïŒã«ã«ã·ãŠã ããã°ãã·ãŠã ïŒåã¯ã¢ã³ã¢
ããŠã å¡©ãæããããšãã§ãããã¢ã³ã¢ããŠã å¡©
ã®å Žåã«ã¯ãç¹ã«ã¢ã³ã¢ãã¢ã®ïŒïŒïŒåã¯ïŒåã®
æ°ŽçŽ ååãã¡ãã«åºããšãã«åºåã¯ïŒâãããã
ã·ãšãã«åºã«ãã眮æãããŠããŠããã¢ã³ã¢ãã¢
åã¯æ¬¡ã®ã¢ãã³ïŒã°ã¢ããžã³ãã¢ã«ããªã³ãã·ã¯
ãããã·ã«ã¢ãã³ããšãã¬ã³ãžã¢ãã³ãããã©ãž
ã³ããèªå°ããããïŒäŸ¡ã®ã«ããªã³åã¯ïŒåã®ïŒ
䟡ã®ã«ããªã³ãæããã¢ãã³ïŒäŸãã°ãšãã¬ã³ãž
ã¢ãã³ïŒã®å Žåãäžè¬åŒã«çžå¿ããã¹ã«ãã³é ž
ã®ååç©ïŒååãæããå¡©ã§ãããã¹ã«ãã³é žå¡©
ã¯äŸãã°äžè¬åŒã®çžå¿ããã¹ã«ãã³é žãšçžå¿ã
ãã¢ã«ã«ãªéå±æ°Žé žåç©åã¯ã¢ã«ã«ãªåé¡éå±æ°Ž
é žåç©åã¯ã¢ã³ã¢ãã¢ãããã¯çžå¿ããã¢ãã³ãš
ãããã®ããã«åžžçšã®æ¹æ³ã§åŸãããã äžè¬åŒã®ããªååç©ã®åºR6ãïŒå眮æãã
ãC2ãC6âã¢ã«ãã«åºã§ãããªãã°ããã®åºã®
眮æåã¯èšèŒãããïŒã€ã®åäžã®ãåã¯ïŒã€ã®ç°
ãªã眮æåãæããŠããŠãããäŸãã°ã次ã®ããª
ååç©ãæããããšãã§ããïŒïŒïŒïŒâãžã¡ã«ã«
ããããããâã«ãããã·ã©ãã³ãã·ã¹ãã€ã³ã
ã«ã«ããã·åºãC1ãC6âã¢ã«ã«ãâã«ã§ãç¹ã«
C1ãC4âã¢ã«ã«ãâã«ã§ãšã¹ãã«åãããŠãã
ã·ã¹ãã€ã³ãäŸãã°ã·ã¹ã€ãã€ã³ã¡ãã«ãšã¹ãã«
åã¯ã·ã¹ãã€ã³ãšãã«ãšã¹ãã«ããã¢ã·ã¹ãã€
ã³ãïŒâã¡ã«ã«ããâïŒïŒïŒâãããã³ãžãªâ
ã«ãïŒïŒïŒâãžã¡ã«ã«ããâãããã³ã¹ã«ãã³
é žãïŒïŒïŒïŒïŒâããªã¡ã«ã«ããâãããã³ãïŒ
âã¡ã«ã«ããâãšã¿ã³ã¹ã«ãã³é žïŒç¹ã«ãããªãŠ
ã å¡©ãšããŠïŒãïŒïŒ2â²âãžããªãžâãšã¿ã³ã¹ã«ã
ã³é žã äžè¬åŒã®ããªååç©ã®å¡©ãšããŠãç¹ã«é žåº
ïŒã«ã«ããã·åºãã¹ã«ãã¢ã«ãã«åºïŒãæããäž
è¬åŒã®ããªååç©ãã圢æãããå¡©ãæããã
ãšãã§ããããã®éãç¹ã«çžå¿ããã¢ã«ã«ãªå¡©
ïŒNaïŒïŒ«ïŒåã¯ã¢ã³ã¢ããŠã å¡©ã§ãããã¢ã³ã¢ã
ãŠã å¡©ã¯äŸãã°ã¢ã³ã¢ãã¢åã¯æ¬¡ã®ã¢ãã³ïŒC1
ãC4âã¢ãã¢ã«ãã«ã¢ãã³ãC1ãC4âãžã¢ã«ã
ã«ã¢ãã³åã¯C1ãC4âããªã¢ã«ãã«ã¢ãã³ãå Ž
åã«ããããããã·ã«åºãæããŠããŠãããåèš
ã¢ãã³ïŒäŸãã°ã¢ãâããžâåã¯ããªãšã¿ãâã«
ã¢ãã³ïŒããšãã¬ã³ãžã¢ãã³ãã³ãªã³ããã¿ã€ã³ã
ã³ã©ãã³ããèªå°ãããããžããªâãžâC2ãC6
âã¢ã«ã«ã³ã¹ã«ãã³é žãå¡©ãšããŠäœ¿çšããå Žåã
ãã®ããã«ç¹ã«äžæ§ã®ã¢ã«ã«ãªå¡©ãããã¯ã¢ã³ã¢
ããŠã å¡©ãæããããšãã§ããã äžè¬åŒã®ååç©ã®ããã€ãã¯ãã§ã«å ¬ç¥ã§ã
ããäžè¬åŒã®æ°èŠååç©ã¯äŸãã°æ¬¡ã®ãã®ã§ã
ãïŒ ïœ äžè¬åŒã®ååç©ã§ãåŒäžR1åã³R3ã¯åäž
åã¯ç°ãªã€ãŠãããæ°ŽçŽ ãã¡ãã«ããšãã«åã¯ïŒ
âã¯ãã«ãšãã«ãè¡šãããR2ã¯æ°ŽçŽ ãã¡ãã«å
ã¯ãšãã«ã§ãããR4ã¯æ°ŽçŽ ã§ãããã€R5ã¯2ãC6
âããããã·ã¢ã«ãã«åºåã¯C2ãC6âã¡ã«ã«ã
ãã¢ã«ãã«åºã§ããããã®éãããã®åºã®ããã
ããä»å çã«ã¡ã«ã«ããåºãæããŠããŠãããå
ã¯R5ã¯ã«ã«ãâC1ãC6âã¢ã«ã³ãã·âC1ãC10â
ã¢ã«ãã«åºãïŒâã¢ããâïŒâïœ ã«ã«ãâC1
ãC6âã¢ã«ã³ãã·âãšãã«åºåã¯ïŒâC2ãC6
âã¢ã«ã«ãã€ã«ã¢ããâïŒâã«ã«ãâC1ãC6
âã¢ã«ã³ãã·âãšãã«åºãè¡šãããããã§åº
R3ãæ°ŽçŽ ä»¥å€ã®ãã®ã§ããå ŽåR2ãïŒâã¯ã
ã«ãšãã«ã§ãã€ãŠããã ïœ äžè¬åŒã®ååç©ã§ãåŒäžR1åã³R2ãã¯ã
ã«ãšãã«åºãè¡šãããR3åã³R4ãæ°ŽçŽ ãè¡šã
ããR5ã¯æŽã«ã¡ã«ã«ããåºãæããŠããŠãã
C2ãC6âã¡ã«ã«ããã¢ã«ãã«åºãã¡ã«ã«ãã
åºãæããŠããŠããããããã·ãã³ãã«åºïŒçŽ
éåã¯åæéïŒãåã¯ã«ã«ãâC1ãC6âã¢ã«ã³
ãã·âC1ãC10âã¢ã«ãã«åºãïŒâã¢ããâïŒ
âã«ã«ãâC1ãC6âã¢ã«ã³ãã·âãšãã«åºå
ã¯ïŒâC2ãC6âã¢ã«ã«ãã€ã«ã¢ããâïŒâã«
ã«ãâC1ãC6âã¢ã«ã³ãã·âãšãã«åºãè¡šã
ãã äžè¬åŒã®ååç©ã®è£œé ã¯äŸãã°å ¬ç¥ã®äžè¬åŒ
ãåŒäžãR1ãR2ãR3åã³R4ã¯ç¹èš±è«æ±ã®ç¯å²
äžäžè¬åŒã«èšèŒã®ãã®ãšåããã®ãè¡šããã
ã¯æ°ŽçŽ åã¯C1ãC4âã¢ã«ãã«åºãè¡šãããã®ïŒ
âããããã·âåã¯ïŒâã¢ã«ã³ãã·âãªããµã¶ã
ã¹ããªã³ãšçžå¿ããäžè¬åŒ ãåŒäžãR5ã¯ç¹èš±è«æ±ã®ç¯å²äžã®äžè¬åŒã«
èšèŒã®ãã®ãšåããã®ãè¡šãããã®ããªâã«ã溶
å€äžæå©ã«é žæ§è§Šåªã®ååšäžã«è¡ãªããé žæ§è§Šåª
ãšããŠã¯äŸãã°ïŒããªã¯ãã«é ¢é žãããªãã«ãªã«
é ¢é žåã¯äžè¬çãªç¡æ©é žåã¯ææ©é žåã¯ïŒ¡ïœ
ïŒãZnc2ãTic4ã®ãããªã«ã€ã¹é žãæããã
ãšãã§ããïŒTetraâhedron Letters第10å·»
ïŒ1979幎ïŒã第883ã886é åã¯Cancer
Chemother.Pharâmacol.第ïŒå·»ïŒ1979幎ïŒã第
181ã188é ïŒã溶å€ãšããŠã¯äŸãã°æ°Žãå¡©åã¡ã
ã¬ã³ãã¢ã«ã³âã«ãç¹ã«ã¡ã¿ãâã«ããšã¿ãâ
ã«ãããããâã«åã¯ã€ãœãã¿ãâã«ã®ãããªäœ
çŽã¢ã«ã³âã«ãç¹ã«ã¢ã»ãã³ã®ãããªäœçŽã¢ã«ã
ã«ã±ãã³ããžã¡ãã«ãã«ã ã¢ããïŒDMFïŒåã¯
é¡äŒŒã®æº¶å€ãããã¯ïŒçš®ä»¥äžã®ããã溶å€ãããª
ãæ··åç©ããã®åå¿ã¯äŸãã°â31âãïŒ40âã®ç¯
å²ã®æž©åºŠã§å®æœããããããªãã¡å Žåã«ããå·åŽ
äžã宀枩åã¯å ç±äžã«å®æœãããã äžè¬åŒã®ååç©ã®åºR5ãC2ãC6âã¹ã«ãã¢
ã«ãã«åºãè¡šããå Žåãçžå¿ããã¹ã«ãã³é žå¡©ã¯
ã¹ã«ãã³é žåºãçžå¿ããå¡©åºã§äžåããããšã«ã
ãåŸããããæŽã«ããã®ãããªå¡©ã«ãããŠã«ããª
ã³ãã€ãªã³äº€æäœäžå ¬ç¥æ³ã§ä»ã®ã«ããªã³ã«äº€æ
ããããšãã§ããããã¡ãããäžè¬åŒã®ååç©
ãçŽæ¥C2ãC6âã¹ã«ãã¢ã«ãã«ã¡ã«ã«ãã¿ã³ã®
çžå¿ããã¹ã«ãã³é žå¡©ããããã¯æŽã«ã¡ã«ã«ãã
åºãæããC2ãC6âã¹ã«ãã¢ã«ãã«ã¡ã«ã«ãã¿
ã³ã®å¡©ãåèšã®ããã«åå¿ãããããšãã§ããã åºçºææãšããŠäœ¿çšããäžè¬åŒã®ååç©ã¯å ¬
ç¥ã§ãããçµæ¶ã®åœ¢ã§åã¯ç²çæç©ã®åœ¢ã§äœ¿çšã
ãããšãã§ããå ¬ç¥æ³ã§æ¬¡ã®ããã«åæããããš
ãã§ããïŒ ïŒâããããã·âãªããµã¶ãã¹ããªã³ã¯ïŒâã
ãããã«ãªãã·èªå°äœã®éå ã«ããåŸãããïŒäŸ
ãã°ãA.ã¿ã«ãã¶ã¯çãJ.Amer.Chem.Soc.ã第
95å·»ã第589é ïŒ1973幎ïŒïŒãïŒâã¢ã«ã³ãã·âãª
ããµã¶ãã¹ããªã³ã¯çžå¿ããã¢ã«ã³âã«äžã§ãã
ããã·èªå°äœããé žæ§è§Šåªäžã«åœ¢æããããã¹ã«
ãã¢ã«ãã«ããªâã«ã¯äŸãã°çžå¿ãããããªãŠã
ããã ã¢ã«ã«ã³ã¹ã«ããâããšããªå°¿çŽ ãšãåå¿
ãããããŠãããŠã å¡©ãšããã¢ã³ã¢ãã¢ã§è±é¢ã
ãããšã«ããåŸãããã次ãã§ããã®ããã«åŸã
ããã¡ã«ã«ããã¢ã«ã«ã³ã¹ã«ãã³é žãææã®ã¹ã«
ãã³é žå¡©ã«å€æããããšãã§ãããæ¬çºæã«ãã
ãªããµã¶ãã¹ããªã³èªå°äœããã©ã»ãäœã®ã·ã¹å
ã³ãã©ã³ã¹ç°æ§äœã補é ãããã äžè¬åŒã®ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããª
ã³ãäžè¬åŒã®ããªååç©ãšäžç·ã«ãäŸãã°æ··å
ç©ã溶å€åã¯ã«ãã»ã«äžã«åé¢ããŠãããªãã¡äž
ç·ã«çµå£åã¯è žç®¡å€é©çšããããšãã§ããããã
ããªãããäžè¬åŒåã³ã®ååç©ãåé¢ããŠã
ããªãã¡åã ã®å»è¬èª¿å€ã®åœ¢ã§äœ¿çšããããšãã§
ãããåŸè ã®å Žåã¯åæã®æäžåã¯ç°ãªãæéã§
ã®æäžãå¯èœã§ãããç°ãªãã¬âã¬ã³åŒèª¿å€åœ¢ã§
äžè¬åŒåã³ã®ååç©ãååšãããªãã°ãåæ
é©çšã®ããã«ã¯äž¡æ¹ã®èª¿å€ãçµå£åã¯è žç®¡å€é©çš
ïŒäŸãã°éèå åã¯è ¹èå ïŒãããåæã§ã¯ãªã
é©çšã®å Žåãäžè¬åŒã®ããªååç©ãå ãçµå£å
ã¯è žç®¡å€é©çšããäžè¬åŒã®ååç©ãããšããè ž
管å€é©çšããã®ãããããã®éãããªååç©ã®
æäžã¯ååç©ã®æäžåã®çŽ120åãååç©ã®
æäžåŸçŽ120åã®éã®æéç¯å²å ã§è¡ãªãããã®
ãè¯ããååç©ã®æäž60ååã10ååŸãæå©ã§
ãããç¹ã«30ååã10ååŸãæå©ã§ããããã®é
ã¯æäžããäºå®ã®ãåã¯æäžããïŒâã¹ã«ãã€ã
âãªããµã¶ãã¹ããªã³ã®éã®ïŒã¢ã«ãããå°ãª
ããšãïŒã¢ã«ãããªååç©ã®æé«èªå®¹æäžéã®
æé«éãäžè¬ã«ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ã
ãªã³ïŒã¢ã«ããã10ã¢ã«ã§ããã äžè¬åŒã®ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããª
ã³ãšåæã«ããªååç©ãæäžããªãå ŽåãäŸã
ã°ããªååç©ã次ã®éã§è žç®¡å€åã¯çµå£æäžãã
ããšãã§ããïŒ ã·ã¹ãã€ã³ïŒïœïŒ42ããªã¢ã«ïŒãããªâã«ãš
ããŠïŒ äŸãã°ïŒâïŒïŒâãããã·ãâãšãã«ã¡ã«ã«ã
ãïŒâã·ã¯ããã¹ãã¢ããïŒP1ïŒ1.4ïœåã¯ïŒâ
ãïŒâïŒãã¹âïŒã¯ãã«ãšãã«ïŒâã¢ããâïŒâãªã
ãœâããã©ãããâ2HâïŒïŒïŒïŒïŒâãªããµã¶
ãã¹ããªã³âïŒâã€ã«âããªãâïŒâã¡ã«ã«ãã
ãããã³ã¹ã«ãã³é žâã·ã¯ãããã·ã«ã¢ãã³å¡©
ïŒä»¥éãã®ååç©ãäžè¬åŒã®ååç©ãšããŠâã·
ã¯ãããã·ã«ã¢ãã³å¡©âãšããïŒ2.3gã®æäžå60
åã®å ŽåïŒP11.4ïœãããã¯ã·ã¯ãããã·ã«ã¢ã
ã³å¡©2.3gã¯ãããããããïŒã€ã®ååç©ã®4.2ã
ãªã¢ã«ã«çžå¿ããïŒã ã·ã¹ãã€ã³2.5gïŒ21ããªã¢ã«ïŒïŒ ååç©P11.4gåã¯ã·ã¯ãããã·ã«ã¢ãã³å¡©2.3g
ã®é©çšãšåæã®å Žåã ã·ã¹ãã€ã³5gïŒ ååç©P11.4gåã¯ã·ã¯ãããã·ã«ã¢ãã³å¡©2.3g
ã®é©çšåŸ30åã®å Žåã åèšã®ããã«ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ã
ãªã³ååç©ã®é©çšååŸã®ããªååç©ã®é©çšã«ãã
ãŠãïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããªã³ã«å¯Ÿã
ãããªååç©ã®ã¢ã«æ¯ã¯äŸãã°10ïŒïŒã§ããã
åæé©çšã®å Žåã¯ïŒïŒïŒã§ãããäŸãã°ãã·ã¹ã
ã€ã³ã®ãããã«ä»ã®ããªååç©ã䜿çšããå Ž
åãäŸãã°åã«èšèŒããã¢ã«æ¯ã«åºã¥ãçžå¿ãã
éãèšç®ããããåæã«P1ã®ãããã«ãäŸãã°
äžè¬åŒã®ä»ã®ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ã
ãªã³ãããã¯çžå¿ããå¡©4.2ããªã¢ã«ã䜿çšãã
ããšãã§ããã ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããªã³ã®éè
å æäžã«ãããŠã¯æ³šå°æéã¯ïŒåããé·ãã®ãè¯
ããäŸãã°ïŒã10åã§ããããã®ã€ã©é©çšãã泚
å°å®¹éã¯è žç®¡å€é©çšã«ãããŠïŒäŸãã°éèå ãè ¹
èå ïŒã泚å°ãããçŽ0.5ã100mlã§ããã®ãããã
ããªãã¡ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããªã³ã®
ã§ããã ãäœãæ¿åºŠã®æº¶æ¶²ãäŸãã°0.1ãïŒïŒ 溶
液ãæå©ã«ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããªã³
ã®0.5ãïŒïŒ 溶液ã䜿çšããããšã§ãããäžè¬
åŒã®ããªååç©äžŠã³ã«ïŒâã¹ã«ãã€ãâãªããµ
ã¶ãã¹ããªã³ãè žç®¡å€é©çšããã®ãæå©ã§ããã
ãã®ããšã¯äž¡æ¹ã®æåãå¥ã ã«æäžããå Žåãã
äžç·ã«æäžããå Žåããªããã€ã äžè¬åŒã®ååç©ãšäžè¬åŒã®ããªååç©ãšã®
æ¬çºæã«ããçµã¿åããã¯äŸãã°S180ç现è
ïŒ106è «ç现èïŒããŠã¹ïŒã®ç§»æ€åŸïŒæ¥ç®ã®NMRI
âããŠã¹*ã«è ¹èå 泚å°ãè¡ãªããšè¯å¥œãªçŽ°èé
æ¢äœçšïŒMethode nach GoldinãJohnsonã
VendittiãPreclinicaãCharaterizataion of
Candidate Antitumor DrugsãCancer
Chemotherapy ReportsããâãïŒã第ïŒå·»ã
1975幎ïŒã瀺ããïŒ*NMRIâããŠã¹ãšã¯
National Medical Research Institutã«ãããŠ
飌è²ãããå®éšåç©ãšããŠåžè²©ãããŠãããïŒäŸ
ãã°åèšå®éšæ³ã«ãããŠãïŒåã®æäžéïŒâïŒïŒ
âããããã·âãšãã«ã¡ã«ã«ããïŒâã·ã¯ããã¹
ãã¢ããïŒïŒP1ïŒ32mgïŒKgåã³ã·ã¹ãã€ã³58
mgïŒKgã«ãããŠãè «çãæããåç©ã®50ïŒ ã®æ²»ç
ãåŸãããP1220mgïŒKgåã³ã·ã¹ãã€ã³392mgïŒ
Kgã®æäžéã§ã¯åç©ã®95ïŒ ãæ²»çãããïŒåã®æ
äžéã·ã¯ãããã·ã«ã¢ãã³å¡©52mgïŒKgåã³ã·ã¹ã
ã€ã³47mgïŒKgã¯åãå®éšæ³ã«ãããŠåæ§ã«å€æ°ã®
è «çåç©ã®æ²»çã«äœçšããã ãããã®çŽ°èéæ¢äœçšã¯å ¬ç¥ã®å»è¬åã·ã¯ãã
ã¹ãã¢ããã®éæ¢äœçšãšæ¯èŒå¯èœã§ããã åèšåç©å®éšã«ãããŠãæãäœãçæ¯æ§äœçšé
ã¯äŸãã°ïŒâïŒïŒâããããã·âãšãã«ã¡ã«ã«ã
ãïŒâã·ã¯ããã¹ãã¢ããïŒP1ïŒãšã·ã¹ãã€ã³ã®
å Žåãè ¹èå æäžP1ïŒmgïŒKgåã³ã·ã¹ãã€ã³ïŒ
mgïŒKgã§ãããã·ã¯ãããã·ã«ã¢ãã³å¡©ïŒã·ã¹ã
ã€ã³ã®çµã¿åããã®å Žåãè ¹èå æäžã·ã¯ããã
ã·ã«ã¢ãã³å¡©8.2mgïŒKgåã³ã·ã¹ãã€ã³7.2mgïŒKg
ã§ããã åèšåç©å®éšã«ãããäœçšã«ãšã€ãŠäžè¬çãªæ
äžç¯å²ãšããŠã¯ãäŸãã°ååç© 10mgïŒKgåã³
ããªååç©ïŒã18mgïŒKgãååç©400mgïŒKg
ããªååç©360ã720mgïŒKgãç¹ã«ååç© 50
mgïŒKgåã³ããªååç©45ã85mgïŒKgãååç©
400mgïŒKgåã³ããªååç©360ã720mgïŒKgã®
æäžéã§ããã æ¬çºæã«ããçµåããã䜿çšããããšã®ã§ãã
çåïŒ ç¹ã«å€§ããªäœè äžã®ãããªãã¡èžèè å åã³è ¹
èå 䞊ã³ã«èè±å ã«éšäœãæãããã¹ãŠã®åœ¢ã®ç
çŸæ£åã³ç転移ãäŸãã°åµå·£çã䞊ã³ã«åæè «ç
ã®è£è¬ååŠçæ³ãåµå·£çåã³ä¹³çåŸã®èžè転移ã
ç¹ã«è ¹æ°Žåã«ãããèžèè å åã³è ¹èå ç転移ã
çåæãããµããæçš®æ§èè±çåã³åçºè «çã®æ
åºæè¡åŸã®è£è¬ååŠçæ³ãåè¢ã®ãç¹ã«é»è²è «ã§
ã®è»éªšéšçã«ãããå±æçåè¢çæµåéã«ãã
ãŠã æŽã«ãæ¬çºæã«ããçµã¿åããã¯å ç«æå§çšå€
ãšããŠã奜é©ã§ããã ç¹ã«ãåèšè «çã®å±æååŠçæ³ã«ãšã€ãŠæ¬çºæ
ã®çµã¿åããã¯æå©ã§ãããããã«ã¯ç¹ã«è å å
åŠçæ³åã³ç³»çµ±çïŒäŸãã°çµå£åã¯è žç®¡å€ïŒäœ¿çš
ãå±ãããè å ååŠçæ³ã«ã¯äŸãã°æ¬¡ã®ãã®ãã
ãã ïœ ç¬¬ãæã®åµå·£çã«ãããè ¹èå æäžäžŠã³
ã«ç¬¬ãæã®åµå·£çã«ãããåææ²»çãç¹ã«
ããã«ã¯åçºè «çã®æåºåŸã®åµå·£çã®è£è¬ååŠ
çæ³ãç¹ã«åµå·£çãä¹³ççã«ããèžè転移ã®å
åŠçæ³ïŒ ïœ è ¹è転移åã³è ¹æ°ŽçïŒAscitidenïŒã«ããã
èžèè å é©çšïŒ ïœ åçæãããµããæçš®æ§èè±çã«ãããŠè£è¬
ååŠçæ³ãšããŠæè¡åŸã«èè±å é©çšïŒ ïœ äžæ¢ç¥çµç³»ã®äžå®ã®è «çã«ãããè³å 宀é©
çšããã®é©çšã¯å ¬ç¥ã®ãªããµã¶ãã¹ããªã³çŽ°è
å¶æ¢å€ã®äœçšåœ¢ã®æµžéæ§ã®æ¬ åŠã«ããååŠçæ³
ã«äœ¿çšãããªãïŒ ïœ äŸãã°ç¹ã«é»è²è «ã«ãããåè¢ã®éªšè «åã³è»
éªšè «ã«ãããå±éšçæµã«ããé©çšïŒ ïœ è©Šéšç®¡å åã³åæ€ç®è¡åã®éªšé«å€ç§»æ€ã«ãã
ã転移ãæããããçæ£è ã®é«æäžâååŠçæ³
ã«ãããèªå·±éªšé«ç§»æ€ ïŒäœçšç©è³ªãè¡ç®¡ãä»ããŠäœå ã«éã°ããïŒ ç³»çµ±ç䜿çšã«ãããŠã¯ãæ¬çºæã«ããçµã¿åã
ãã®äœ¿çšã«ããæ²»çäœçšãéãããããã®æ²»çäœ
çšã¯å ¬ç¥ã®æšæºçè¬å€ã·ã¯ããã¹ãã¢ããã®äœçš
ãšæ¯èŒå¯èœã§ãããã·ã¯ããã¹ãã¢ããåã³é¡äŒŒ
ã®è¬å€ã«å¯Ÿããæ¬çºæã«ããçµã¿åããã®å©ç¹ã¯
ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããªã³ã¯ãã§ã«çŽ
æ¥çæ¯ãšããŠäœçšããã®ã§ãäŸãã°ãã®äœçšãæ
æ©äœäžã§è¡ãªãããé µçŽ ç代è¬åå¿ïŒé·æéãèŠ
ããïŒã®åŸã¯ãããŠç€ºãããã·ã¯ããã¹ãã¢ãã
ããç®æšãå®ããè¯å¥œã«é éããããšãã§ãããš
ããããšã§ãããåŸã€ãŠãäžè¬åŒã®ããªååç©
ãšçµã¿åãããïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ã
ãªã³ã¯ç³»çµ±çïŒäŸãã°éèå ïŒäœ¿çšã«ãããŠè¬å
åŠã«ããã調ç¯ãå¯èœãšããããã«ããççŸæ£ã«
ãããæé©ãªç³»çµ±çååŠçæ³ãšå€çš®ååŠçæ³ãå¯
èœãšãããæŽã«ãæ¬çºæã®çµã¿åããã¯éªšé«æ¯æ§
ã®åã«ãªããµã¶ãã¹ããªã³ã§ã®ååŠçæ³ãéå®ã
ãèŠå ã§ãããªããµã¶ãã¹ããªã³ã®å ¬ç¥å°¿æ¯æ§å¯
äœçšã¯å®è³ªçã«å®å šã«æ¶å€±ããã ããããŠãäŸãã°ããŠã¹ã«ããããã€ãããšã
ãéèå åã¯è ¹èå é©çšã«ãããŠïŒâïŒïŒâãã
ããã·ãšãã«ã¡ã«ã«ããïŒâã·ã¯ããã¹ãã¢ãã
ã®DL* 50ã¯ãã·ã¹ãã€ã³ã®ïŒåã¢ã«éå°ã®ååšäž
ã«æ³šå°ãè¡ãªãæïŒãïŒåïŒã·ã¯ãããã·ã«ã¢ã
ã³å¡©ã®é©çšã®å Žåã¯ïŒãïŒåïŒã«äžæããïŒ*
DL50ã¯äœ¿çšããåç©ã®50ïŒ ãæ»äº¡ããæäžéã§
ããïŒããã®éãL1210ç现è**ïŒè©Šéšå®å ïŒå
ã¯L1210åã³S180ç现èïŒçäœå ïŒã«å¯Ÿãã现è
æ¯å¹æã¯è žç®¡å€é©çšã«ãããŠã»ãšãã©æžå°ããªã
ïŒL1210ç现èãšã¯ããŠã¹ã®ãªã³ãæ§çœè¡ç ç现
èã§ãããããã¯å®éšç®çã®ããã®ã¹ã¿ã³ãâã
âç现èãšããŠäœ¿çšãããè «çãã³ã¯ïŒäŸãã°ã
ãã€ãã«ãã«ã°ã®Deuches
KrebsforschungszentrumïŒã§æã«å ¥ãããåžè²©
ããããŠããïŒãããããŠãæ¬çºæã«ããçµã¿å
ããã¯ãäžè¬åŒã®è£è·å€âããªååç©ãªãã«ïŒ
âïŒïŒâããããã·âãšãã«ã¡ã«ã«ããïŒâãªããµ
ã¶ãã¹ããªã³åã¯ã·ã¯ãããã·ã«ã¢ãã³å¡©ãåç¬
ã«äœ¿çšããã®ã«æ¯èŒããŠïŒåãïŒåã«æ²»çç¯å²ã
åºãããã äžè¬åŒã®ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããª
ã³ãããªååç©ãšçµã¿åãããéã«ãäžè¬ã«
0.5mgã3500mgãæå©ã«50ã2000mgãç¹ã«200ã
1400mgã䜿çšããããšãã§ãããã®éãã®æäžé
ã¯æº¶è§£ããã圢ïŒäŸãã°ã氎溶液ãããã¯ççé£
å¡©æ°Žã®åœ¢ïŒã§åã¯åºäœã®åœ¢ïŒäŸãã°ãé å€åã¯ã«
ãã»ã«ïŒã§ãã€ãŠããããã®æäžéã¯ïŒæ¥ïŒã10
åã«æäžããŠããã äžè¬åŒã®ããªååç©ã®äœ¿çšéã¯äžè¬åŒã®ïŒ
âã¹ã«ãã€ãâãªããµã¶ãã¹ããªã³ïŒãããã¯ã
ã®å¡©ïŒïŒã¢ã«ã«å¯Ÿãäžè¬ã«0.2ã10ã¢ã«ãç¹ã«0.2
ãïŒã¢ã«ãæå©ã«0.4ãïŒã¢ã«ã§ãããäžè¬åŒ
ã®ããªååç©ãC2ãC6âã¹ã«ãã¢ã«ãã«åºãå«
æããŠããå ŽåãäŸãã°ïŒâã¹ã«ãã€ãâãªããµ
ã¶ãã¹ããªã³ ïŒã¢ã«ãããååç©0.2ãïŒ
ã¢ã«ã䜿çšãããäžè¬åŒã®ããªååç©ãå šãã¹
ã«ãã¢ã«ãã«åºãå«æããŠããªããªãã°ãäžè¬ã«
ããªååç©ãé«æäžéãäŸãã°ïŒâã¹ã«ãã€ã
âãªããµã¶ãã¹ããªã³ïŒã¢ã«ã«å¯Ÿãããªååç©
ïŒã10ã¢ã«ã§äœ¿çšãããããªååç©ã«å¯Ÿãã
ååç©ïŒãããã¯ãã®å¡©ïŒã®æ··åæ¯ã¯ãååç©
ïŒãããã¯ãã®å¡©ïŒïŒããªååç©ïŒïŒã¢ã«ïŒ
0.2ã¢ã«ãïŒã¢ã«ïŒ10ã¢ã«ã§ãããäŸãã°ïŒïŒïŒ
ãïŒïŒ10ãããã¯ïŒïŒïŒãïŒïŒïŒïŒããããã¢ã«ïŒ
ã§ãããããªãã¡ãäŸãã°ååç© 337mgïŒïŒ
âïŒïŒâããããã·âãšãã«ã¡ã«ã«ããïŒâã·ã¯ã
ãã¹ãã¢ããïŒïŒããªã¢ã«ã®å ŽåïŒã䜿çšãããª
ãã°ãåæã«åã¯ç°ãªã€ãæç¹ã«ããªååç©ãš
ããŠäŸãã°ã·ã¹ãã€ã³121ã1210mgïŒïŒããªã¢ã«
ã10ããªã¢ã«ïŒã䜿çšããããšãã§ããããã®å Ž
åä»ã®äžè¬åŒã®ããªååç©ã䜿çšãããªãã°ã
ç°ãªãã¢ã«ééã«çžå¿ããç°ãªãmgã§ã®æäžéã
èšç®ãããäžè¬ã«ãäžè¬åŒã®ïŒâã¹ã«ãã€ãâ
ãªããµã¶ãã¹ããªã³åã³ãã®ã€ã©äœ¿çšããç¹å®ã®
äžè¬åŒã®ããªååç©ã«å¿ããŠäžè¬åŒã®ããªå
åç©ã0.1mgã25ïœãæå©ã«ïŒmgã5gãç¹ã«10mg
ã5gãããã¯10mgã3.5ïœã®éã§äœ¿çšããã äŸãã°ãå»è¬èª¿å€ã¯äžè¬åŒã®ååç©30ã40mg
ïŒã·ã¹ãã€ã³20ã100mgïŒåã¯åŒã®ä»ã®ããªå
åç©ã®çžå¿ããã¢ã«éïŒãäžè¬åŒã®ååç©1230
ã1300mgïŒã·ã¹ãã€ã³1600ã4500mgïŒåã¯åŒã®
ä»ã®ããªååç©ã®çžå¿ããã¢ã«éïŒãå«æããŠã
ããæå©ãªäœ¿çšåœ¢ã¯æŽ»æ§ç©è³ª0.1ã13ïŒ ãå«æã
ã溶液ã§ããããã®éãã®èšèŒã¯äžè¬åŒã®ïŒâ
ã¹ã«ãã€ãâãªããµã¶ãã¹ããªã³ãšäžè¬åŒã®ã
ãªååç©ãããªãæ··åç©ã«é¢ããŠããåäžæ¹ã®æ
åãããªãã¡äžè¬åŒã®ïŒâã¹ã«ãã€ãâãªããµ
ã¶ãã¹ããªã³ã®ã¿åã³äžè¬åŒã®ããªååç©ã®ã¿
ãå«æããçžå¿ãã溶液ã«é¢ããŠã該åœããã åŒã®ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããªã³ãš
äžè¬åŒã®ããªååç©ã®ïŒåæäžéã¯äŸãã°è žç®¡
å€é©çšã«ãããŠååç©10.5mgïŒååç©0.3mgã
ååç©13.5ïœããªååç©13gãæå©ã«ååç©150
mgïŒããªååç©936mgãååç©12gïŒããªåå
ç©7gãç¹ã«ååç© 100mgïŒããªååç©72
mgãååç© 1.4gïŒããªååç©5gã§ãããçµ
å£é©çšã«ãããŠã¯ïŒåã®æäžéã¯äŸãã°ååç©
250mgïŒããªååç©450mgã§ãããäŸãã°ãéè
å 泚å°ã«ãããŠã¯æ¯æ¥ïŒåP1100mgïŒã·ã¹ãã€ã³
180mgïŒãããã¯ã·ã¯ããžãã·ã«ã¢ãã³å¡©162mgïŒ
ã·ã¹ãã€ã³146mgïŒãP11.0gïŒã·ã¹ãã€ã³1.8gïŒã
ããã¯ã·ã¯ãããã·ã«ã¢ãã³å¡©1.62gïŒã·ã¹ãã€
ã³1.46gïŒãå«æãã容éïŒã20mlã®ã¢ã³ãã«ïŒ
æ¬ãè¯ããåãããšã¯ä»ã®äžè¬åŒã®ïŒâã¹ã«ã
ã€ãâãªããµã¶ãã¹ããªã³åã³äžè¬åŒã®ããªå
åç©ã«é¢ããŠãèšãããããŠã¹ã§ã®ïŒâïŒïŒâã
ãããã·âãšãã«ã¡ã«ã«ããâã·ã¯ããã¹ãã¢ã
ãïŒã·ã¹ãã€ã³ã®çµã¿åããã®NMRIâããŠã¹
ã§ã®æ¥æ§æ¯æ§ïŒDL50ïŒã¯äŸãã°éèå é©çšã§ïŒ
âïŒïŒâããããã·âãšãã«ã¡ã«ã«ããâã·ã¯ã
ãã¹ãã¢ãã600mgïŒKgïŒã·ã¹ãã€ã³1100mgã§ã
ãã äžè¬ã«ãçµã¿åããïŒâã¹ã«ãã€ãâãªããµã¶
ãã¹ããªã³ïŒããªååç©ã«ãšã€ãŠããŠã¹ïŒKg
ãããã®DL50ã¯ååç©1300ã1200mgïŒããªåå
ç©108mgã2.1gãæå©ã«ã¯ååç©1400mgã1000
mgïŒããªååç©290mgã1.8ïœãç¹ã«ååç©1500
mgã800mgïŒããªååç©360mgã1.5gã§ãããïŒ
âã¹ã«ãã€ãâãªããµã¶ãã¹ããªã³ãšããªåå
ç©ãšã®ã¢ã«æ··åæ¯ïŒïŒïŒãïŒïŒïŒã§ã®çµã¿åã
ãã®å Žåã®æ倧蚱容éã¯ïŒâã¹ã«ãã€ãâãªããµ
ã¶ãã¹ããªã³æåã«é¢ããŠçŽ50mgïŒKgïŒäººã®äœ
éïŒã§ããã ãã®çµã¿åããã¯å»åŠã«ãããŠãç£å»åŠã«ãã
ãŠããããåç¬ã§äœ¿çšããŠããåã¯ä»ã®è¬ç掻æ§
ç©è³ªãšäžç·ã«äœ¿çšããŠãããã æ¬çºæã«ããçµåããã®çŽ°èéæ¢äœçšã¯äžè¬åŒ
ã®ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããªã³ã®äœçš
ã«èµ·å ããïŒããããªãããããã®ååç©ã¯ãã®
é«ãå±ææ¯æ§ã«ããæ£ããæ²»çã«ã¯ããŸã奜é©ã§
ã¯ãªããäžè¬åŒã®ïŒâã¹ã«ãã€ãâãªããµã¶ã
ã¹ããªã³äžR5ãC2ãC6âã¹ã«ãã€ãã¢ã«ãã«åº
ã§ããå Žåã ãèããæ¯æ§ãäœããåç¬ã§ããã
ãªãã¡äžè¬åŒã®ããªååç©ãšçµã¿åãããã«äœ¿
çšããããšãã§ããã äžè¬åŒïŒåŒäžR5ãC2ãC6âã¹ã«ãã€ãã¢ã«
ãã«åºã§ãããããªãã®ãé€ãïŒã®ïŒâã¹ã«ãã€
ãâãªããµã¶ãã¹ããªã³ã®äœçšã¯æ¬¡ã®ããšããæ
ããã«ãªãïŒ äŸãã°ãNMRIâããŠã¹ã«ïŒå¹ãããS180â
è «ç现è106ã移æ€ããåŸãïŒæ¥ç®ã«è žç®¡å€æ³šå°
ãããšDC* 50ããŠã¹ã®äœéïŒKgããã18mgã§ãã
ïŒDC50ïŒæ²»çéãããã¯è «çãæããåç©ã®50ïŒ
ãæ²»çããæäžéã§ãããDC50ã¯TherãGrund
agen der experimentaen Arzneimitte
forschungïŒVeragsgeseschaft Stuttgartã
1965幎ãã«ãã枬å®ããïŒã110mgïŒKgã®ïŒåæäž
éã«ãããŠãåç©ã®95ïŒ ãå埩ãããäŸãã°ãç
æ¯æ§äœçšã瀺ãæãäœãæäžéã¯è ¹èå é©çšã«ã
ããŠ2.5mgïŒKgã§ãããåèšã®åç©å®éšã«ãããŠ
äœçšã®ããã®äžè¬çæäžéãšããŠã¯ãäŸãã°ïŒ
mgïŒKgã100mgïŒKgãæå©ã«20ã100mgïŒKgããã
ãããšãã§ããã äžè¬åŒã®ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããª
ã³ã®åç¬ã§ã®äœ¿çšãããªãã¡äžè¬åŒã®ããªåå
ç©ãšçµã¿åãããªã䜿çšã«ãããŠã¯çžå¿ããå»è¬
調å€ã¯ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããªã³ãäŸ
ãã°0.25ã1500mgãæå©ã«50ã1250mgãç¹ã«300
ã1000mgå«æããŠããŠãããæå©ãªäœ¿çšåœ¢ã¯ãã
ã§ãåæ§ã«æº¶æ¶²ïŒæ°Žæº¶æ¶²åã¯ççé£å¡©æ°ŽïŒã§ã
ãã掻æ§ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããªã³
0.5ãïŒïŒ ãå«æãããïŒâã¹ã«ãã€ãâãªããµ
ã¶ãã¹ããªã³ã®ïŒåæäžéã¯äŸãã°ãéèå 泚å°
ã§20ã1250mgãè ¹èå åã³èžèè å 泚å°ã§0.25ã
1500mgãæå©ã«50ã1250mgã§ãããäŸãã°ãéè
å 泚å°ã«ãããŠã¯å 容éïŒãïŒmlã§ãïŒâã¹ã«ã
ã€ãâãªããµã¶ãã¹ããªã³50ã200mgãå«æãã
ã¢ã³ãã«ïŒæ¬ããããïŒâã¹ã«ãã€ãâãªããµã¶
ãã¹ããªã³ã®åç¬äœ¿çšã¯äŸãã°åšç®¡çæµã«ãããŠ
åã¯èžè転移ã®ååŠçæ³ã«äœ¿çšãããã NMRIããŠã¹ã®DL50ã¯äŸãã°R5ãC2ãC6âã
ãããã·âã¢ã«ãã«åºãã°ã«ã¿ããªãã«åºåã¯å Ž
åã«ããâååã§ã¢ã·ã«åãããåºâCH2â
CHïŒNH2ïŒCO2ã§ããäžè¬åŒã®ïŒâã¹ã«ã
ã€ãâãªããµã¶ãã¹ããªã³ã§ã¯åç¬äœ¿çšã®å Žåé
èå 泚å°ã§ããŠã¹ã®äœéïŒKgããã250ã470mgã
è ¹èå é©çšã«ãããŠã¯200ã300mgïŒKgã§ããã
R5ãC2ãC6âã¹ã«ãã¢ã«ãã«åºã§ããäžè¬åŒ
ã®ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããªã³ã®DL50
ã¯äŸãã°éèå é©çšïŒã©ããïŒã§ã¯316mgïŒKgã§
ããïŒè ¹èå é©çšïŒããŠã¹ïŒã«ãããŠã¯300mgïŒ
Kgã§ããïŒçµå£æäžïŒããŠã¹ïŒã§ã¯1000mgïŒKgã
ã倧ã§ããã åŒäžãR5ãC2ãC6âã¹ã«ãã¢ã«ãã«åºã§ãã
äžè¬åŒã®ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããªã³
åã³ãã®å¡©ã¯äžè¬ã«ãã匷åã«äœçšãæããããŸ
ãæ¯æ§ã§ã¯ãªãããã®ååç©ã®DL50ã¯ïŒåã®é
èå æäžã«ãããŠãäŸãã°çŽ300ã470mgïŒKgã§ã
ãïŒåŸã€ãŠããããã®ååç©ã¯æšæºèª¿å€ã·ã¯ãã
ã¹ãã¢ãããšåãæ²»çäœçšã瀺ãããã·ã¯ããã¹
ãã¢ããããçŽ20ã50ïŒ äœãæ¥æ§æ¯æ§ã瀺ãïŒã·
ã¯ããã¹ãã¢ããã®ïŒåã®éèå æäžã«ããã
DL50ã¯244mgïŒKgã§ãããïŒããããŠãäŸãã°ã©
ããBDçš®ã®ãªã³ãæ§çœè¡ç L5222ã®å Žåçœè¡
ç æ¥çš®åŸïŒæ¥ç®ã«äžåã®éèå æäžã«ãããŠ
DL50ã¯åŒäžR5ãC2ãC6âã¹ã«ãã€ãã¢ã«ãã«åº
ã§ããåŒã®ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããª
ã³åã³è©²ååç©ã®å¡©ã¯ã·ã¯ããã¹ãã¢ãããšåæ§
1.5mgïŒKgã§ãããã¹ãã©âã¯ã»ãâãªâïŒã©ã
ãïŒSpragueâDaweyâRatteïŒã®ååŠéææ§
ãšã·ãâè ¹æ°Žâèè «ïŒLinie AH13ïŒã«ãããŠã¯
ïŒmgïŒKgã§ããã äžè¬åŒã®ååç©ã®æ¯æ§ã®äžè¬åŒã®ããªåå
ç©ãšã®æ¬çºæã«ããçµã¿åããã«ããæžå°ã¯äŸã
ã°æ¬¡ã®å®éšã«ããéããããïŒ æ¥æ§æ¯æ§ ãã¢ïŒTherïŒèãã°ã«ã³ãã©âã²ã³ã»ãã«ã»
ãšã¯ã¹ããªã¡ã³ãã¬ã³ã»ã¢ã«ããã€ãããã«ãã«
ã·ãŠã³ã°ïŒïŒ§undagen der experimente
en ArzneimitteforschungïŒãMBHåºç瀟
ïŒMBHVeragsgessschaftïŒãã¹ããŠããã¬
ã«ãã1965幎ã«ãã枬å®ã äŸãã°ãéã®NMRIâããŠã¹ïŒ20ã25gïŒã«é
èå åã³è ¹èå æäžããŠïŒâïŒïŒâããããã·â
ãšãã«ã¡ã«ã«ããïŒâã·ã¯ããã¹ãã¢ããïŒP1ïŒ
ã®æ¥æ§æ¯æ§ã次ã®ããã«æž¬å®ããã
ïŒïŒïŒïŒïŒåã¯ïŒãè¡šãããã®ååç©ã¯å ¬ç¥ã§ã
ãããã®ååç©ã¯æè «çäœçšãæãããåæã«é
åžžã«æ¯æ§ã§ããïŒTetrahedron Letters第10å·»
ïŒ1979幎ïŒã第883ã886é ïŒCancer Chemother.
Pharmacol.第ïŒå·»ïŒ1979幎ïŒç¬¬181ã188é å
ç §ïŒã æŽã«ãã«ã³ãµâã»ããªâãã¡ã³ãã»ã¬ãâã
ïŒCanser Treatment ReportsïŒç¬¬60å·»ïŒ1976
幎ïŒã第355ã359é ã«ã¯ïŒâããããã·âã·ã¯ã
ãã¹ãã¢ãããšã·ã¹ãã€ã³ãâã¢ã»ãã«âã·ã¹
ãã€ã³åã³ã°ã«ã¿ããªã³ããã®äžè¬åŒ ãåŒäžãR5â³ã¯âCH2âCHïŒNH2ïŒâCO2å
ã¯âCH2âCHïŒNHCOCH3ïŒâCO2ãè¡šããã
ã®ååç©ã®è£œé ãèšèŒãããŠããã æ¬çºæã¯ç¹èš±è«æ±ã®ç¯å²ã«èšèŒããã課é¡ã«é¢
ããã äžè¬åŒã®ååç©ãšäžè¬åŒã®ååç©ã®æ¬çºæ
ã«ãã䜿çšã«ããäžè¬æ¯æ§ã®èããæžå°ãšåæã«
è¯å¥œãªç现èæ¯äœçšãéããããã®ã§ãæ¬çºæã«
ããçµåããã«ãã€ãŠççŸæ£ã®å±æååŠçæ³åã³
æé©ãªç³»çµ±çååŠçæ³ãå¯èœãšãªãã äžè¬åŒã®ååç©ã¯çš®ã ã®ç«äœç°æ§äœãäŸãã°
ã©ã»ãâããšããŠãå åŠæŽ»æ§ååç©ãšããŠåã¯ãž
ã¢ã¹ãã¬ãªãâïŒã·ã¹åã³ãã©ã³ã¹åïŒãšããŠå
åšãããäžè¬åŒã®ååç©ãšã¯ãã¹ãŠã®å¯èœãªç«
äœç°æ§ã®ååç©åã³ãããã®æ··åç©ãè¡šãããäž
è¬åŒã®ãã®ãããªååç©ã®è£œé ã¯äŸãã°ç¹é¡æ
57â44779å·æ现æžïŒè¥¿ãã€ãåœç¹èš±åºé¡
p3220432.9å·æ现æžãããã¯åp3111428.8å·æ现
æžïŒäžã«èšèŒããæ¹æ³ã«ããè¡ãªãããšãã§ã
ãã äžè¬åŒåã³äžè¬åŒã®ååç©ã«ãããããã
ãã·ã¢ã«ãã«åºãã¡ã«ã«ããã¢ã«ãã«åºã¯çŽéå
ã¯åæéã§ãã€ãŠãããããããã·åºãã¡ã«ã«ã
ãåºãã«ã«ããã·åºäžŠã³ã«ã¹ã«ãã³é žåºã¯ããã
ãã®ã¢ã«ãã«åºã®Ïäœã«ããã®ãæå©ã§ãããç¹
ã«ã¢ã«ãã«åºãšããŠã¯ççŽ ååæ°ïŒãïŒãç¹ã«ïŒ
ã®ãã®ãæå©ã§ãããåãããã«ãäžè¬åŒã®å
åç©ã®C2ãC6âã¢ã«ãã«åºã¯æå©ã«ççŽ ååæ°
ïŒãïŒã®ãã®ã§ãããäžè¬åŒã®R6ãC2ãC6â
ã¢ã«ã«ãã€ã«ã¢ããåºã«ãã眮æãããŠããC2
ãC6âã¢ã«ãã«åºãè¡šããå ŽåãC2ãC6âã¢ã«
ã«ãã€ã«ã¯äŸãã°ã¢ã»ãã«ãããããªãã«ããã
ãªã«ãã€ãœãããªã«ãtertâãããªã«ãè¡šããã R5ãã«ã«ãâC1ãC6âã¢ã«ã³ãã·âC1ãC10â
ã¢ã«ãã«åºãè¡šããå ŽåãC1ãC10âã¢ã«ãã«åº
ã¯æå©ã«ççŽ ååæ°ïŒãïŒã§ãããç¹ã«ççŽ åå
æ°ïŒïŒïŒïŒïŒïŒïŒåã¯ïŒã§ãããã«ã«ãâC1ã
C6âã¢ã«ã³ãã·åºã®æåãšããŠC1ãC6âã¢ã«ã³
ãã·åºã¯äžè¬ã«æå©ã«ççŽ ååæ°ïŒãïŒãæå©ã«
ççŽ ååïŒåã¯ïŒã§ããã äžè¬åŒã®åºR7ãC2ãC6âã¹ã«ãã¢ã«ãã«ã
ãªåºã§ããå Žåãäžè¬åŒHOâSO2âïœïœâ
ââïœïœâSO2âOHã®ãžããªâãžâC2ãC6
âã¢ã«ã«ã³ã¹ã«ãã³é žãè¡šãããããã§ã¯ïœïœ
ãšã¯ççŽ ååæ°ïŒãïŒã®çŽéåã¯åæéã¢ã«ãã¬
ã³åºã§ãããæå©ã«ïœïœã¯âCH2âCH2âã§ã
ãã C2ãC6âã¹ã«ãã¢ã«ãã«åºïŒäžè¬åŒã®åºR5ïŒ
ã«ååšããã¡ã«ã«ããåºã¯äŸãã°ã¢ã«ãã¬ã³éã®
ïŒâãïŒâãïŒâãïŒâåã¯ïŒâäœã®ççŽ åå
ïŒãã³ããªã³ã°ã¯ã¹ã«ãã³é žåºããéå§ããïŒã«
äœçœ®ãããããããªããã¡ã«ã«ããåºã¯ãªããµã¶
ãã¹ããªãã«âïŒïŒïŒâããªåºãšçµåããã¢ã«ãã¬
ã³éã®ççŽ ååã«ååšããªããŠãããã ç¹ã«ãåŒäžR5ãåèšã®ãã®ãè¡šãããåºR1ã
R4ã次ã®æå³ãæããååç©ãæå©ã§ããïŒ R1åã³R2ïŒïŒâã¯ãã«âãšãã«ãR3åã³R4
ïŒïŒšïŒ R1ãR2åã³R3ïŒïŒâã¯ãã«âãšãã«ãR4ïŒ
ïŒšïŒ R1åã³R3ïŒïŒâã¯ãã«âãšãã«ãR2åã³R4
ïŒïŒšã äžè¬åŒã®ããªååç©ãšããŠã¯ç¹ã«R7ãæ°ŽçŽ
ã§ããäžè¬åŒã®ååç©ãæããããšãã§ããã äžè¬åŒã®ååç©ãã¹ã«ãã³é žåºãæããå Ž
åããã®ã¹ã«ãã³é žåºãšå¡©ã圢æããããšã«ãã
çããäžè¬åŒã®ååç©ã®æ²»çäžäœ¿çšå¯èœãªå¡©ã
䜿çšããããšãã§ãããç¹ã«ããã®å Žåã¢ã«ã«ãª
éå±å¡©ïŒã«ãªãŠã ããããªãŠã ïŒãã¢ã«ã«ãªåé¡
éå±å¡©ïŒã«ã«ã·ãŠã ããã°ãã·ãŠã ïŒåã¯ã¢ã³ã¢
ããŠã å¡©ãæããããšãã§ãããã¢ã³ã¢ããŠã å¡©
ã®å Žåã«ã¯ãç¹ã«ã¢ã³ã¢ãã¢ã®ïŒïŒïŒåã¯ïŒåã®
æ°ŽçŽ ååãã¡ãã«åºããšãã«åºåã¯ïŒâãããã
ã·ãšãã«åºã«ãã眮æãããŠããŠããã¢ã³ã¢ãã¢
åã¯æ¬¡ã®ã¢ãã³ïŒã°ã¢ããžã³ãã¢ã«ããªã³ãã·ã¯
ãããã·ã«ã¢ãã³ããšãã¬ã³ãžã¢ãã³ãããã©ãž
ã³ããèªå°ããããïŒäŸ¡ã®ã«ããªã³åã¯ïŒåã®ïŒ
䟡ã®ã«ããªã³ãæããã¢ãã³ïŒäŸãã°ãšãã¬ã³ãž
ã¢ãã³ïŒã®å Žåãäžè¬åŒã«çžå¿ããã¹ã«ãã³é ž
ã®ååç©ïŒååãæããå¡©ã§ãããã¹ã«ãã³é žå¡©
ã¯äŸãã°äžè¬åŒã®çžå¿ããã¹ã«ãã³é žãšçžå¿ã
ãã¢ã«ã«ãªéå±æ°Žé žåç©åã¯ã¢ã«ã«ãªåé¡éå±æ°Ž
é žåç©åã¯ã¢ã³ã¢ãã¢ãããã¯çžå¿ããã¢ãã³ãš
ãããã®ããã«åžžçšã®æ¹æ³ã§åŸãããã äžè¬åŒã®ããªååç©ã®åºR6ãïŒå眮æãã
ãC2ãC6âã¢ã«ãã«åºã§ãããªãã°ããã®åºã®
眮æåã¯èšèŒãããïŒã€ã®åäžã®ãåã¯ïŒã€ã®ç°
ãªã眮æåãæããŠããŠãããäŸãã°ã次ã®ããª
ååç©ãæããããšãã§ããïŒïŒïŒïŒâãžã¡ã«ã«
ããããããâã«ãããã·ã©ãã³ãã·ã¹ãã€ã³ã
ã«ã«ããã·åºãC1ãC6âã¢ã«ã«ãâã«ã§ãç¹ã«
C1ãC4âã¢ã«ã«ãâã«ã§ãšã¹ãã«åãããŠãã
ã·ã¹ãã€ã³ãäŸãã°ã·ã¹ã€ãã€ã³ã¡ãã«ãšã¹ãã«
åã¯ã·ã¹ãã€ã³ãšãã«ãšã¹ãã«ããã¢ã·ã¹ãã€
ã³ãïŒâã¡ã«ã«ããâïŒïŒïŒâãããã³ãžãªâ
ã«ãïŒïŒïŒâãžã¡ã«ã«ããâãããã³ã¹ã«ãã³
é žãïŒïŒïŒïŒïŒâããªã¡ã«ã«ããâãããã³ãïŒ
âã¡ã«ã«ããâãšã¿ã³ã¹ã«ãã³é žïŒç¹ã«ãããªãŠ
ã å¡©ãšããŠïŒãïŒïŒ2â²âãžããªãžâãšã¿ã³ã¹ã«ã
ã³é žã äžè¬åŒã®ããªååç©ã®å¡©ãšããŠãç¹ã«é žåº
ïŒã«ã«ããã·åºãã¹ã«ãã¢ã«ãã«åºïŒãæããäž
è¬åŒã®ããªååç©ãã圢æãããå¡©ãæããã
ãšãã§ããããã®éãç¹ã«çžå¿ããã¢ã«ã«ãªå¡©
ïŒNaïŒïŒ«ïŒåã¯ã¢ã³ã¢ããŠã å¡©ã§ãããã¢ã³ã¢ã
ãŠã å¡©ã¯äŸãã°ã¢ã³ã¢ãã¢åã¯æ¬¡ã®ã¢ãã³ïŒC1
ãC4âã¢ãã¢ã«ãã«ã¢ãã³ãC1ãC4âãžã¢ã«ã
ã«ã¢ãã³åã¯C1ãC4âããªã¢ã«ãã«ã¢ãã³ãå Ž
åã«ããããããã·ã«åºãæããŠããŠãããåèš
ã¢ãã³ïŒäŸãã°ã¢ãâããžâåã¯ããªãšã¿ãâã«
ã¢ãã³ïŒããšãã¬ã³ãžã¢ãã³ãã³ãªã³ããã¿ã€ã³ã
ã³ã©ãã³ããèªå°ãããããžããªâãžâC2ãC6
âã¢ã«ã«ã³ã¹ã«ãã³é žãå¡©ãšããŠäœ¿çšããå Žåã
ãã®ããã«ç¹ã«äžæ§ã®ã¢ã«ã«ãªå¡©ãããã¯ã¢ã³ã¢
ããŠã å¡©ãæããããšãã§ããã äžè¬åŒã®ååç©ã®ããã€ãã¯ãã§ã«å ¬ç¥ã§ã
ããäžè¬åŒã®æ°èŠååç©ã¯äŸãã°æ¬¡ã®ãã®ã§ã
ãïŒ ïœ äžè¬åŒã®ååç©ã§ãåŒäžR1åã³R3ã¯åäž
åã¯ç°ãªã€ãŠãããæ°ŽçŽ ãã¡ãã«ããšãã«åã¯ïŒ
âã¯ãã«ãšãã«ãè¡šãããR2ã¯æ°ŽçŽ ãã¡ãã«å
ã¯ãšãã«ã§ãããR4ã¯æ°ŽçŽ ã§ãããã€R5ã¯2ãC6
âããããã·ã¢ã«ãã«åºåã¯C2ãC6âã¡ã«ã«ã
ãã¢ã«ãã«åºã§ããããã®éãããã®åºã®ããã
ããä»å çã«ã¡ã«ã«ããåºãæããŠããŠãããå
ã¯R5ã¯ã«ã«ãâC1ãC6âã¢ã«ã³ãã·âC1ãC10â
ã¢ã«ãã«åºãïŒâã¢ããâïŒâïœ ã«ã«ãâC1
ãC6âã¢ã«ã³ãã·âãšãã«åºåã¯ïŒâC2ãC6
âã¢ã«ã«ãã€ã«ã¢ããâïŒâã«ã«ãâC1ãC6
âã¢ã«ã³ãã·âãšãã«åºãè¡šãããããã§åº
R3ãæ°ŽçŽ ä»¥å€ã®ãã®ã§ããå ŽåR2ãïŒâã¯ã
ã«ãšãã«ã§ãã€ãŠããã ïœ äžè¬åŒã®ååç©ã§ãåŒäžR1åã³R2ãã¯ã
ã«ãšãã«åºãè¡šãããR3åã³R4ãæ°ŽçŽ ãè¡šã
ããR5ã¯æŽã«ã¡ã«ã«ããåºãæããŠããŠãã
C2ãC6âã¡ã«ã«ããã¢ã«ãã«åºãã¡ã«ã«ãã
åºãæããŠããŠããããããã·ãã³ãã«åºïŒçŽ
éåã¯åæéïŒãåã¯ã«ã«ãâC1ãC6âã¢ã«ã³
ãã·âC1ãC10âã¢ã«ãã«åºãïŒâã¢ããâïŒ
âã«ã«ãâC1ãC6âã¢ã«ã³ãã·âãšãã«åºå
ã¯ïŒâC2ãC6âã¢ã«ã«ãã€ã«ã¢ããâïŒâã«
ã«ãâC1ãC6âã¢ã«ã³ãã·âãšãã«åºãè¡šã
ãã äžè¬åŒã®ååç©ã®è£œé ã¯äŸãã°å ¬ç¥ã®äžè¬åŒ
ãåŒäžãR1ãR2ãR3åã³R4ã¯ç¹èš±è«æ±ã®ç¯å²
äžäžè¬åŒã«èšèŒã®ãã®ãšåããã®ãè¡šããã
ã¯æ°ŽçŽ åã¯C1ãC4âã¢ã«ãã«åºãè¡šãããã®ïŒ
âããããã·âåã¯ïŒâã¢ã«ã³ãã·âãªããµã¶ã
ã¹ããªã³ãšçžå¿ããäžè¬åŒ ãåŒäžãR5ã¯ç¹èš±è«æ±ã®ç¯å²äžã®äžè¬åŒã«
èšèŒã®ãã®ãšåããã®ãè¡šãããã®ããªâã«ã溶
å€äžæå©ã«é žæ§è§Šåªã®ååšäžã«è¡ãªããé žæ§è§Šåª
ãšããŠã¯äŸãã°ïŒããªã¯ãã«é ¢é žãããªãã«ãªã«
é ¢é žåã¯äžè¬çãªç¡æ©é žåã¯ææ©é žåã¯ïŒ¡ïœ
ïŒãZnc2ãTic4ã®ãããªã«ã€ã¹é žãæããã
ãšãã§ããïŒTetraâhedron Letters第10å·»
ïŒ1979幎ïŒã第883ã886é åã¯Cancer
Chemother.Pharâmacol.第ïŒå·»ïŒ1979幎ïŒã第
181ã188é ïŒã溶å€ãšããŠã¯äŸãã°æ°Žãå¡©åã¡ã
ã¬ã³ãã¢ã«ã³âã«ãç¹ã«ã¡ã¿ãâã«ããšã¿ãâ
ã«ãããããâã«åã¯ã€ãœãã¿ãâã«ã®ãããªäœ
çŽã¢ã«ã³âã«ãç¹ã«ã¢ã»ãã³ã®ãããªäœçŽã¢ã«ã
ã«ã±ãã³ããžã¡ãã«ãã«ã ã¢ããïŒDMFïŒåã¯
é¡äŒŒã®æº¶å€ãããã¯ïŒçš®ä»¥äžã®ããã溶å€ãããª
ãæ··åç©ããã®åå¿ã¯äŸãã°â31âãïŒ40âã®ç¯
å²ã®æž©åºŠã§å®æœããããããªãã¡å Žåã«ããå·åŽ
äžã宀枩åã¯å ç±äžã«å®æœãããã äžè¬åŒã®ååç©ã®åºR5ãC2ãC6âã¹ã«ãã¢
ã«ãã«åºãè¡šããå Žåãçžå¿ããã¹ã«ãã³é žå¡©ã¯
ã¹ã«ãã³é žåºãçžå¿ããå¡©åºã§äžåããããšã«ã
ãåŸããããæŽã«ããã®ãããªå¡©ã«ãããŠã«ããª
ã³ãã€ãªã³äº€æäœäžå ¬ç¥æ³ã§ä»ã®ã«ããªã³ã«äº€æ
ããããšãã§ããããã¡ãããäžè¬åŒã®ååç©
ãçŽæ¥C2ãC6âã¹ã«ãã¢ã«ãã«ã¡ã«ã«ãã¿ã³ã®
çžå¿ããã¹ã«ãã³é žå¡©ããããã¯æŽã«ã¡ã«ã«ãã
åºãæããC2ãC6âã¹ã«ãã¢ã«ãã«ã¡ã«ã«ãã¿
ã³ã®å¡©ãåèšã®ããã«åå¿ãããããšãã§ããã åºçºææãšããŠäœ¿çšããäžè¬åŒã®ååç©ã¯å ¬
ç¥ã§ãããçµæ¶ã®åœ¢ã§åã¯ç²çæç©ã®åœ¢ã§äœ¿çšã
ãããšãã§ããå ¬ç¥æ³ã§æ¬¡ã®ããã«åæããããš
ãã§ããïŒ ïŒâããããã·âãªããµã¶ãã¹ããªã³ã¯ïŒâã
ãããã«ãªãã·èªå°äœã®éå ã«ããåŸãããïŒäŸ
ãã°ãA.ã¿ã«ãã¶ã¯çãJ.Amer.Chem.Soc.ã第
95å·»ã第589é ïŒ1973幎ïŒïŒãïŒâã¢ã«ã³ãã·âãª
ããµã¶ãã¹ããªã³ã¯çžå¿ããã¢ã«ã³âã«äžã§ãã
ããã·èªå°äœããé žæ§è§Šåªäžã«åœ¢æããããã¹ã«
ãã¢ã«ãã«ããªâã«ã¯äŸãã°çžå¿ãããããªãŠã
ããã ã¢ã«ã«ã³ã¹ã«ããâããšããªå°¿çŽ ãšãåå¿
ãããããŠãããŠã å¡©ãšããã¢ã³ã¢ãã¢ã§è±é¢ã
ãããšã«ããåŸãããã次ãã§ããã®ããã«åŸã
ããã¡ã«ã«ããã¢ã«ã«ã³ã¹ã«ãã³é žãææã®ã¹ã«
ãã³é žå¡©ã«å€æããããšãã§ãããæ¬çºæã«ãã
ãªããµã¶ãã¹ããªã³èªå°äœããã©ã»ãäœã®ã·ã¹å
ã³ãã©ã³ã¹ç°æ§äœã補é ãããã äžè¬åŒã®ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããª
ã³ãäžè¬åŒã®ããªååç©ãšäžç·ã«ãäŸãã°æ··å
ç©ã溶å€åã¯ã«ãã»ã«äžã«åé¢ããŠãããªãã¡äž
ç·ã«çµå£åã¯è žç®¡å€é©çšããããšãã§ããããã
ããªãããäžè¬åŒåã³ã®ååç©ãåé¢ããŠã
ããªãã¡åã ã®å»è¬èª¿å€ã®åœ¢ã§äœ¿çšããããšãã§
ãããåŸè ã®å Žåã¯åæã®æäžåã¯ç°ãªãæéã§
ã®æäžãå¯èœã§ãããç°ãªãã¬âã¬ã³åŒèª¿å€åœ¢ã§
äžè¬åŒåã³ã®ååç©ãååšãããªãã°ãåæ
é©çšã®ããã«ã¯äž¡æ¹ã®èª¿å€ãçµå£åã¯è žç®¡å€é©çš
ïŒäŸãã°éèå åã¯è ¹èå ïŒãããåæã§ã¯ãªã
é©çšã®å Žåãäžè¬åŒã®ããªååç©ãå ãçµå£å
ã¯è žç®¡å€é©çšããäžè¬åŒã®ååç©ãããšããè ž
管å€é©çšããã®ãããããã®éãããªååç©ã®
æäžã¯ååç©ã®æäžåã®çŽ120åãååç©ã®
æäžåŸçŽ120åã®éã®æéç¯å²å ã§è¡ãªãããã®
ãè¯ããååç©ã®æäž60ååã10ååŸãæå©ã§
ãããç¹ã«30ååã10ååŸãæå©ã§ããããã®é
ã¯æäžããäºå®ã®ãåã¯æäžããïŒâã¹ã«ãã€ã
âãªããµã¶ãã¹ããªã³ã®éã®ïŒã¢ã«ãããå°ãª
ããšãïŒã¢ã«ãããªååç©ã®æé«èªå®¹æäžéã®
æé«éãäžè¬ã«ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ã
ãªã³ïŒã¢ã«ããã10ã¢ã«ã§ããã äžè¬åŒã®ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããª
ã³ãšåæã«ããªååç©ãæäžããªãå ŽåãäŸã
ã°ããªååç©ã次ã®éã§è žç®¡å€åã¯çµå£æäžãã
ããšãã§ããïŒ ã·ã¹ãã€ã³ïŒïœïŒ42ããªã¢ã«ïŒãããªâã«ãš
ããŠïŒ äŸãã°ïŒâïŒïŒâãããã·ãâãšãã«ã¡ã«ã«ã
ãïŒâã·ã¯ããã¹ãã¢ããïŒP1ïŒ1.4ïœåã¯ïŒâ
ãïŒâïŒãã¹âïŒã¯ãã«ãšãã«ïŒâã¢ããâïŒâãªã
ãœâããã©ãããâ2HâïŒïŒïŒïŒïŒâãªããµã¶
ãã¹ããªã³âïŒâã€ã«âããªãâïŒâã¡ã«ã«ãã
ãããã³ã¹ã«ãã³é žâã·ã¯ãããã·ã«ã¢ãã³å¡©
ïŒä»¥éãã®ååç©ãäžè¬åŒã®ååç©ãšããŠâã·
ã¯ãããã·ã«ã¢ãã³å¡©âãšããïŒ2.3gã®æäžå60
åã®å ŽåïŒP11.4ïœãããã¯ã·ã¯ãããã·ã«ã¢ã
ã³å¡©2.3gã¯ãããããããïŒã€ã®ååç©ã®4.2ã
ãªã¢ã«ã«çžå¿ããïŒã ã·ã¹ãã€ã³2.5gïŒ21ããªã¢ã«ïŒïŒ ååç©P11.4gåã¯ã·ã¯ãããã·ã«ã¢ãã³å¡©2.3g
ã®é©çšãšåæã®å Žåã ã·ã¹ãã€ã³5gïŒ ååç©P11.4gåã¯ã·ã¯ãããã·ã«ã¢ãã³å¡©2.3g
ã®é©çšåŸ30åã®å Žåã åèšã®ããã«ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ã
ãªã³ååç©ã®é©çšååŸã®ããªååç©ã®é©çšã«ãã
ãŠãïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããªã³ã«å¯Ÿã
ãããªååç©ã®ã¢ã«æ¯ã¯äŸãã°10ïŒïŒã§ããã
åæé©çšã®å Žåã¯ïŒïŒïŒã§ãããäŸãã°ãã·ã¹ã
ã€ã³ã®ãããã«ä»ã®ããªååç©ã䜿çšããå Ž
åãäŸãã°åã«èšèŒããã¢ã«æ¯ã«åºã¥ãçžå¿ãã
éãèšç®ããããåæã«P1ã®ãããã«ãäŸãã°
äžè¬åŒã®ä»ã®ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ã
ãªã³ãããã¯çžå¿ããå¡©4.2ããªã¢ã«ã䜿çšãã
ããšãã§ããã ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããªã³ã®éè
å æäžã«ãããŠã¯æ³šå°æéã¯ïŒåããé·ãã®ãè¯
ããäŸãã°ïŒã10åã§ããããã®ã€ã©é©çšãã泚
å°å®¹éã¯è žç®¡å€é©çšã«ãããŠïŒäŸãã°éèå ãè ¹
èå ïŒã泚å°ãããçŽ0.5ã100mlã§ããã®ãããã
ããªãã¡ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããªã³ã®
ã§ããã ãäœãæ¿åºŠã®æº¶æ¶²ãäŸãã°0.1ãïŒïŒ 溶
液ãæå©ã«ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããªã³
ã®0.5ãïŒïŒ 溶液ã䜿çšããããšã§ãããäžè¬
åŒã®ããªååç©äžŠã³ã«ïŒâã¹ã«ãã€ãâãªããµ
ã¶ãã¹ããªã³ãè žç®¡å€é©çšããã®ãæå©ã§ããã
ãã®ããšã¯äž¡æ¹ã®æåãå¥ã ã«æäžããå Žåãã
äžç·ã«æäžããå Žåããªããã€ã äžè¬åŒã®ååç©ãšäžè¬åŒã®ããªååç©ãšã®
æ¬çºæã«ããçµã¿åããã¯äŸãã°S180ç现è
ïŒ106è «ç现èïŒããŠã¹ïŒã®ç§»æ€åŸïŒæ¥ç®ã®NMRI
âããŠã¹*ã«è ¹èå 泚å°ãè¡ãªããšè¯å¥œãªçŽ°èé
æ¢äœçšïŒMethode nach GoldinãJohnsonã
VendittiãPreclinicaãCharaterizataion of
Candidate Antitumor DrugsãCancer
Chemotherapy ReportsããâãïŒã第ïŒå·»ã
1975幎ïŒã瀺ããïŒ*NMRIâããŠã¹ãšã¯
National Medical Research Institutã«ãããŠ
飌è²ãããå®éšåç©ãšããŠåžè²©ãããŠãããïŒäŸ
ãã°åèšå®éšæ³ã«ãããŠãïŒåã®æäžéïŒâïŒïŒ
âããããã·âãšãã«ã¡ã«ã«ããïŒâã·ã¯ããã¹
ãã¢ããïŒïŒP1ïŒ32mgïŒKgåã³ã·ã¹ãã€ã³58
mgïŒKgã«ãããŠãè «çãæããåç©ã®50ïŒ ã®æ²»ç
ãåŸãããP1220mgïŒKgåã³ã·ã¹ãã€ã³392mgïŒ
Kgã®æäžéã§ã¯åç©ã®95ïŒ ãæ²»çãããïŒåã®æ
äžéã·ã¯ãããã·ã«ã¢ãã³å¡©52mgïŒKgåã³ã·ã¹ã
ã€ã³47mgïŒKgã¯åãå®éšæ³ã«ãããŠåæ§ã«å€æ°ã®
è «çåç©ã®æ²»çã«äœçšããã ãããã®çŽ°èéæ¢äœçšã¯å ¬ç¥ã®å»è¬åã·ã¯ãã
ã¹ãã¢ããã®éæ¢äœçšãšæ¯èŒå¯èœã§ããã åèšåç©å®éšã«ãããŠãæãäœãçæ¯æ§äœçšé
ã¯äŸãã°ïŒâïŒïŒâããããã·âãšãã«ã¡ã«ã«ã
ãïŒâã·ã¯ããã¹ãã¢ããïŒP1ïŒãšã·ã¹ãã€ã³ã®
å Žåãè ¹èå æäžP1ïŒmgïŒKgåã³ã·ã¹ãã€ã³ïŒ
mgïŒKgã§ãããã·ã¯ãããã·ã«ã¢ãã³å¡©ïŒã·ã¹ã
ã€ã³ã®çµã¿åããã®å Žåãè ¹èå æäžã·ã¯ããã
ã·ã«ã¢ãã³å¡©8.2mgïŒKgåã³ã·ã¹ãã€ã³7.2mgïŒKg
ã§ããã åèšåç©å®éšã«ãããäœçšã«ãšã€ãŠäžè¬çãªæ
äžç¯å²ãšããŠã¯ãäŸãã°ååç© 10mgïŒKgåã³
ããªååç©ïŒã18mgïŒKgãååç©400mgïŒKg
ããªååç©360ã720mgïŒKgãç¹ã«ååç© 50
mgïŒKgåã³ããªååç©45ã85mgïŒKgãååç©
400mgïŒKgåã³ããªååç©360ã720mgïŒKgã®
æäžéã§ããã æ¬çºæã«ããçµåããã䜿çšããããšã®ã§ãã
çåïŒ ç¹ã«å€§ããªäœè äžã®ãããªãã¡èžèè å åã³è ¹
èå 䞊ã³ã«èè±å ã«éšäœãæãããã¹ãŠã®åœ¢ã®ç
çŸæ£åã³ç転移ãäŸãã°åµå·£çã䞊ã³ã«åæè «ç
ã®è£è¬ååŠçæ³ãåµå·£çåã³ä¹³çåŸã®èžè転移ã
ç¹ã«è ¹æ°Žåã«ãããèžèè å åã³è ¹èå ç転移ã
çåæãããµããæçš®æ§èè±çåã³åçºè «çã®æ
åºæè¡åŸã®è£è¬ååŠçæ³ãåè¢ã®ãç¹ã«é»è²è «ã§
ã®è»éªšéšçã«ãããå±æçåè¢çæµåéã«ãã
ãŠã æŽã«ãæ¬çºæã«ããçµã¿åããã¯å ç«æå§çšå€
ãšããŠã奜é©ã§ããã ç¹ã«ãåèšè «çã®å±æååŠçæ³ã«ãšã€ãŠæ¬çºæ
ã®çµã¿åããã¯æå©ã§ãããããã«ã¯ç¹ã«è å å
åŠçæ³åã³ç³»çµ±çïŒäŸãã°çµå£åã¯è žç®¡å€ïŒäœ¿çš
ãå±ãããè å ååŠçæ³ã«ã¯äŸãã°æ¬¡ã®ãã®ãã
ãã ïœ ç¬¬ãæã®åµå·£çã«ãããè ¹èå æäžäžŠã³
ã«ç¬¬ãæã®åµå·£çã«ãããåææ²»çãç¹ã«
ããã«ã¯åçºè «çã®æåºåŸã®åµå·£çã®è£è¬ååŠ
çæ³ãç¹ã«åµå·£çãä¹³ççã«ããèžè転移ã®å
åŠçæ³ïŒ ïœ è ¹è転移åã³è ¹æ°ŽçïŒAscitidenïŒã«ããã
èžèè å é©çšïŒ ïœ åçæãããµããæçš®æ§èè±çã«ãããŠè£è¬
ååŠçæ³ãšããŠæè¡åŸã«èè±å é©çšïŒ ïœ äžæ¢ç¥çµç³»ã®äžå®ã®è «çã«ãããè³å 宀é©
çšããã®é©çšã¯å ¬ç¥ã®ãªããµã¶ãã¹ããªã³çŽ°è
å¶æ¢å€ã®äœçšåœ¢ã®æµžéæ§ã®æ¬ åŠã«ããååŠçæ³
ã«äœ¿çšãããªãïŒ ïœ äŸãã°ç¹ã«é»è²è «ã«ãããåè¢ã®éªšè «åã³è»
éªšè «ã«ãããå±éšçæµã«ããé©çšïŒ ïœ è©Šéšç®¡å åã³åæ€ç®è¡åã®éªšé«å€ç§»æ€ã«ãã
ã転移ãæããããçæ£è ã®é«æäžâååŠçæ³
ã«ãããèªå·±éªšé«ç§»æ€ ïŒäœçšç©è³ªãè¡ç®¡ãä»ããŠäœå ã«éã°ããïŒ ç³»çµ±ç䜿çšã«ãããŠã¯ãæ¬çºæã«ããçµã¿åã
ãã®äœ¿çšã«ããæ²»çäœçšãéãããããã®æ²»çäœ
çšã¯å ¬ç¥ã®æšæºçè¬å€ã·ã¯ããã¹ãã¢ããã®äœçš
ãšæ¯èŒå¯èœã§ãããã·ã¯ããã¹ãã¢ããåã³é¡äŒŒ
ã®è¬å€ã«å¯Ÿããæ¬çºæã«ããçµã¿åããã®å©ç¹ã¯
ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããªã³ã¯ãã§ã«çŽ
æ¥çæ¯ãšããŠäœçšããã®ã§ãäŸãã°ãã®äœçšãæ
æ©äœäžã§è¡ãªãããé µçŽ ç代è¬åå¿ïŒé·æéãèŠ
ããïŒã®åŸã¯ãããŠç€ºãããã·ã¯ããã¹ãã¢ãã
ããç®æšãå®ããè¯å¥œã«é éããããšãã§ãããš
ããããšã§ãããåŸã€ãŠãäžè¬åŒã®ããªååç©
ãšçµã¿åãããïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ã
ãªã³ã¯ç³»çµ±çïŒäŸãã°éèå ïŒäœ¿çšã«ãããŠè¬å
åŠã«ããã調ç¯ãå¯èœãšããããã«ããççŸæ£ã«
ãããæé©ãªç³»çµ±çååŠçæ³ãšå€çš®ååŠçæ³ãå¯
èœãšãããæŽã«ãæ¬çºæã®çµã¿åããã¯éªšé«æ¯æ§
ã®åã«ãªããµã¶ãã¹ããªã³ã§ã®ååŠçæ³ãéå®ã
ãèŠå ã§ãããªããµã¶ãã¹ããªã³ã®å ¬ç¥å°¿æ¯æ§å¯
äœçšã¯å®è³ªçã«å®å šã«æ¶å€±ããã ããããŠãäŸãã°ããŠã¹ã«ããããã€ãããšã
ãéèå åã¯è ¹èå é©çšã«ãããŠïŒâïŒïŒâãã
ããã·ãšãã«ã¡ã«ã«ããïŒâã·ã¯ããã¹ãã¢ãã
ã®DL* 50ã¯ãã·ã¹ãã€ã³ã®ïŒåã¢ã«éå°ã®ååšäž
ã«æ³šå°ãè¡ãªãæïŒãïŒåïŒã·ã¯ãããã·ã«ã¢ã
ã³å¡©ã®é©çšã®å Žåã¯ïŒãïŒåïŒã«äžæããïŒ*
DL50ã¯äœ¿çšããåç©ã®50ïŒ ãæ»äº¡ããæäžéã§
ããïŒããã®éãL1210ç现è**ïŒè©Šéšå®å ïŒå
ã¯L1210åã³S180ç现èïŒçäœå ïŒã«å¯Ÿãã现è
æ¯å¹æã¯è žç®¡å€é©çšã«ãããŠã»ãšãã©æžå°ããªã
ïŒL1210ç现èãšã¯ããŠã¹ã®ãªã³ãæ§çœè¡ç ç现
èã§ãããããã¯å®éšç®çã®ããã®ã¹ã¿ã³ãâã
âç现èãšããŠäœ¿çšãããè «çãã³ã¯ïŒäŸãã°ã
ãã€ãã«ãã«ã°ã®Deuches
KrebsforschungszentrumïŒã§æã«å ¥ãããåžè²©
ããããŠããïŒãããããŠãæ¬çºæã«ããçµã¿å
ããã¯ãäžè¬åŒã®è£è·å€âããªååç©ãªãã«ïŒ
âïŒïŒâããããã·âãšãã«ã¡ã«ã«ããïŒâãªããµ
ã¶ãã¹ããªã³åã¯ã·ã¯ãããã·ã«ã¢ãã³å¡©ãåç¬
ã«äœ¿çšããã®ã«æ¯èŒããŠïŒåãïŒåã«æ²»çç¯å²ã
åºãããã äžè¬åŒã®ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããª
ã³ãããªååç©ãšçµã¿åãããéã«ãäžè¬ã«
0.5mgã3500mgãæå©ã«50ã2000mgãç¹ã«200ã
1400mgã䜿çšããããšãã§ãããã®éãã®æäžé
ã¯æº¶è§£ããã圢ïŒäŸãã°ã氎溶液ãããã¯ççé£
å¡©æ°Žã®åœ¢ïŒã§åã¯åºäœã®åœ¢ïŒäŸãã°ãé å€åã¯ã«
ãã»ã«ïŒã§ãã€ãŠããããã®æäžéã¯ïŒæ¥ïŒã10
åã«æäžããŠããã äžè¬åŒã®ããªååç©ã®äœ¿çšéã¯äžè¬åŒã®ïŒ
âã¹ã«ãã€ãâãªããµã¶ãã¹ããªã³ïŒãããã¯ã
ã®å¡©ïŒïŒã¢ã«ã«å¯Ÿãäžè¬ã«0.2ã10ã¢ã«ãç¹ã«0.2
ãïŒã¢ã«ãæå©ã«0.4ãïŒã¢ã«ã§ãããäžè¬åŒ
ã®ããªååç©ãC2ãC6âã¹ã«ãã¢ã«ãã«åºãå«
æããŠããå ŽåãäŸãã°ïŒâã¹ã«ãã€ãâãªããµ
ã¶ãã¹ããªã³ ïŒã¢ã«ãããååç©0.2ãïŒ
ã¢ã«ã䜿çšãããäžè¬åŒã®ããªååç©ãå šãã¹
ã«ãã¢ã«ãã«åºãå«æããŠããªããªãã°ãäžè¬ã«
ããªååç©ãé«æäžéãäŸãã°ïŒâã¹ã«ãã€ã
âãªããµã¶ãã¹ããªã³ïŒã¢ã«ã«å¯Ÿãããªååç©
ïŒã10ã¢ã«ã§äœ¿çšãããããªååç©ã«å¯Ÿãã
ååç©ïŒãããã¯ãã®å¡©ïŒã®æ··åæ¯ã¯ãååç©
ïŒãããã¯ãã®å¡©ïŒïŒããªååç©ïŒïŒã¢ã«ïŒ
0.2ã¢ã«ãïŒã¢ã«ïŒ10ã¢ã«ã§ãããäŸãã°ïŒïŒïŒ
ãïŒïŒ10ãããã¯ïŒïŒïŒãïŒïŒïŒïŒããããã¢ã«ïŒ
ã§ãããããªãã¡ãäŸãã°ååç© 337mgïŒïŒ
âïŒïŒâããããã·âãšãã«ã¡ã«ã«ããïŒâã·ã¯ã
ãã¹ãã¢ããïŒïŒããªã¢ã«ã®å ŽåïŒã䜿çšãããª
ãã°ãåæã«åã¯ç°ãªã€ãæç¹ã«ããªååç©ãš
ããŠäŸãã°ã·ã¹ãã€ã³121ã1210mgïŒïŒããªã¢ã«
ã10ããªã¢ã«ïŒã䜿çšããããšãã§ããããã®å Ž
åä»ã®äžè¬åŒã®ããªååç©ã䜿çšãããªãã°ã
ç°ãªãã¢ã«ééã«çžå¿ããç°ãªãmgã§ã®æäžéã
èšç®ãããäžè¬ã«ãäžè¬åŒã®ïŒâã¹ã«ãã€ãâ
ãªããµã¶ãã¹ããªã³åã³ãã®ã€ã©äœ¿çšããç¹å®ã®
äžè¬åŒã®ããªååç©ã«å¿ããŠäžè¬åŒã®ããªå
åç©ã0.1mgã25ïœãæå©ã«ïŒmgã5gãç¹ã«10mg
ã5gãããã¯10mgã3.5ïœã®éã§äœ¿çšããã äŸãã°ãå»è¬èª¿å€ã¯äžè¬åŒã®ååç©30ã40mg
ïŒã·ã¹ãã€ã³20ã100mgïŒåã¯åŒã®ä»ã®ããªå
åç©ã®çžå¿ããã¢ã«éïŒãäžè¬åŒã®ååç©1230
ã1300mgïŒã·ã¹ãã€ã³1600ã4500mgïŒåã¯åŒã®
ä»ã®ããªååç©ã®çžå¿ããã¢ã«éïŒãå«æããŠã
ããæå©ãªäœ¿çšåœ¢ã¯æŽ»æ§ç©è³ª0.1ã13ïŒ ãå«æã
ã溶液ã§ããããã®éãã®èšèŒã¯äžè¬åŒã®ïŒâ
ã¹ã«ãã€ãâãªããµã¶ãã¹ããªã³ãšäžè¬åŒã®ã
ãªååç©ãããªãæ··åç©ã«é¢ããŠããåäžæ¹ã®æ
åãããªãã¡äžè¬åŒã®ïŒâã¹ã«ãã€ãâãªããµ
ã¶ãã¹ããªã³ã®ã¿åã³äžè¬åŒã®ããªååç©ã®ã¿
ãå«æããçžå¿ãã溶液ã«é¢ããŠã該åœããã åŒã®ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããªã³ãš
äžè¬åŒã®ããªååç©ã®ïŒåæäžéã¯äŸãã°è žç®¡
å€é©çšã«ãããŠååç©10.5mgïŒååç©0.3mgã
ååç©13.5ïœããªååç©13gãæå©ã«ååç©150
mgïŒããªååç©936mgãååç©12gïŒããªåå
ç©7gãç¹ã«ååç© 100mgïŒããªååç©72
mgãååç© 1.4gïŒããªååç©5gã§ãããçµ
å£é©çšã«ãããŠã¯ïŒåã®æäžéã¯äŸãã°ååç©
250mgïŒããªååç©450mgã§ãããäŸãã°ãéè
å 泚å°ã«ãããŠã¯æ¯æ¥ïŒåP1100mgïŒã·ã¹ãã€ã³
180mgïŒãããã¯ã·ã¯ããžãã·ã«ã¢ãã³å¡©162mgïŒ
ã·ã¹ãã€ã³146mgïŒãP11.0gïŒã·ã¹ãã€ã³1.8gïŒã
ããã¯ã·ã¯ãããã·ã«ã¢ãã³å¡©1.62gïŒã·ã¹ãã€
ã³1.46gïŒãå«æãã容éïŒã20mlã®ã¢ã³ãã«ïŒ
æ¬ãè¯ããåãããšã¯ä»ã®äžè¬åŒã®ïŒâã¹ã«ã
ã€ãâãªããµã¶ãã¹ããªã³åã³äžè¬åŒã®ããªå
åç©ã«é¢ããŠãèšãããããŠã¹ã§ã®ïŒâïŒïŒâã
ãããã·âãšãã«ã¡ã«ã«ããâã·ã¯ããã¹ãã¢ã
ãïŒã·ã¹ãã€ã³ã®çµã¿åããã®NMRIâããŠã¹
ã§ã®æ¥æ§æ¯æ§ïŒDL50ïŒã¯äŸãã°éèå é©çšã§ïŒ
âïŒïŒâããããã·âãšãã«ã¡ã«ã«ããâã·ã¯ã
ãã¹ãã¢ãã600mgïŒKgïŒã·ã¹ãã€ã³1100mgã§ã
ãã äžè¬ã«ãçµã¿åããïŒâã¹ã«ãã€ãâãªããµã¶
ãã¹ããªã³ïŒããªååç©ã«ãšã€ãŠããŠã¹ïŒKg
ãããã®DL50ã¯ååç©1300ã1200mgïŒããªåå
ç©108mgã2.1gãæå©ã«ã¯ååç©1400mgã1000
mgïŒããªååç©290mgã1.8ïœãç¹ã«ååç©1500
mgã800mgïŒããªååç©360mgã1.5gã§ãããïŒ
âã¹ã«ãã€ãâãªããµã¶ãã¹ããªã³ãšããªåå
ç©ãšã®ã¢ã«æ··åæ¯ïŒïŒïŒãïŒïŒïŒã§ã®çµã¿åã
ãã®å Žåã®æ倧蚱容éã¯ïŒâã¹ã«ãã€ãâãªããµ
ã¶ãã¹ããªã³æåã«é¢ããŠçŽ50mgïŒKgïŒäººã®äœ
éïŒã§ããã ãã®çµã¿åããã¯å»åŠã«ãããŠãç£å»åŠã«ãã
ãŠããããåç¬ã§äœ¿çšããŠããåã¯ä»ã®è¬ç掻æ§
ç©è³ªãšäžç·ã«äœ¿çšããŠãããã æ¬çºæã«ããçµåããã®çŽ°èéæ¢äœçšã¯äžè¬åŒ
ã®ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããªã³ã®äœçš
ã«èµ·å ããïŒããããªãããããã®ååç©ã¯ãã®
é«ãå±ææ¯æ§ã«ããæ£ããæ²»çã«ã¯ããŸã奜é©ã§
ã¯ãªããäžè¬åŒã®ïŒâã¹ã«ãã€ãâãªããµã¶ã
ã¹ããªã³äžR5ãC2ãC6âã¹ã«ãã€ãã¢ã«ãã«åº
ã§ããå Žåã ãèããæ¯æ§ãäœããåç¬ã§ããã
ãªãã¡äžè¬åŒã®ããªååç©ãšçµã¿åãããã«äœ¿
çšããããšãã§ããã äžè¬åŒïŒåŒäžR5ãC2ãC6âã¹ã«ãã€ãã¢ã«
ãã«åºã§ãããããªãã®ãé€ãïŒã®ïŒâã¹ã«ãã€
ãâãªããµã¶ãã¹ããªã³ã®äœçšã¯æ¬¡ã®ããšããæ
ããã«ãªãïŒ äŸãã°ãNMRIâããŠã¹ã«ïŒå¹ãããS180â
è «ç现è106ã移æ€ããåŸãïŒæ¥ç®ã«è žç®¡å€æ³šå°
ãããšDC* 50ããŠã¹ã®äœéïŒKgããã18mgã§ãã
ïŒDC50ïŒæ²»çéãããã¯è «çãæããåç©ã®50ïŒ
ãæ²»çããæäžéã§ãããDC50ã¯TherãGrund
agen der experimentaen Arzneimitte
forschungïŒVeragsgeseschaft Stuttgartã
1965幎ãã«ãã枬å®ããïŒã110mgïŒKgã®ïŒåæäž
éã«ãããŠãåç©ã®95ïŒ ãå埩ãããäŸãã°ãç
æ¯æ§äœçšã瀺ãæãäœãæäžéã¯è ¹èå é©çšã«ã
ããŠ2.5mgïŒKgã§ãããåèšã®åç©å®éšã«ãããŠ
äœçšã®ããã®äžè¬çæäžéãšããŠã¯ãäŸãã°ïŒ
mgïŒKgã100mgïŒKgãæå©ã«20ã100mgïŒKgããã
ãããšãã§ããã äžè¬åŒã®ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããª
ã³ã®åç¬ã§ã®äœ¿çšãããªãã¡äžè¬åŒã®ããªåå
ç©ãšçµã¿åãããªã䜿çšã«ãããŠã¯çžå¿ããå»è¬
調å€ã¯ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããªã³ãäŸ
ãã°0.25ã1500mgãæå©ã«50ã1250mgãç¹ã«300
ã1000mgå«æããŠããŠãããæå©ãªäœ¿çšåœ¢ã¯ãã
ã§ãåæ§ã«æº¶æ¶²ïŒæ°Žæº¶æ¶²åã¯ççé£å¡©æ°ŽïŒã§ã
ãã掻æ§ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããªã³
0.5ãïŒïŒ ãå«æãããïŒâã¹ã«ãã€ãâãªããµ
ã¶ãã¹ããªã³ã®ïŒåæäžéã¯äŸãã°ãéèå 泚å°
ã§20ã1250mgãè ¹èå åã³èžèè å 泚å°ã§0.25ã
1500mgãæå©ã«50ã1250mgã§ãããäŸãã°ãéè
å 泚å°ã«ãããŠã¯å 容éïŒãïŒmlã§ãïŒâã¹ã«ã
ã€ãâãªããµã¶ãã¹ããªã³50ã200mgãå«æãã
ã¢ã³ãã«ïŒæ¬ããããïŒâã¹ã«ãã€ãâãªããµã¶
ãã¹ããªã³ã®åç¬äœ¿çšã¯äŸãã°åšç®¡çæµã«ãããŠ
åã¯èžè転移ã®ååŠçæ³ã«äœ¿çšãããã NMRIããŠã¹ã®DL50ã¯äŸãã°R5ãC2ãC6âã
ãããã·âã¢ã«ãã«åºãã°ã«ã¿ããªãã«åºåã¯å Ž
åã«ããâååã§ã¢ã·ã«åãããåºâCH2â
CHïŒNH2ïŒCO2ã§ããäžè¬åŒã®ïŒâã¹ã«ã
ã€ãâãªããµã¶ãã¹ããªã³ã§ã¯åç¬äœ¿çšã®å Žåé
èå 泚å°ã§ããŠã¹ã®äœéïŒKgããã250ã470mgã
è ¹èå é©çšã«ãããŠã¯200ã300mgïŒKgã§ããã
R5ãC2ãC6âã¹ã«ãã¢ã«ãã«åºã§ããäžè¬åŒ
ã®ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããªã³ã®DL50
ã¯äŸãã°éèå é©çšïŒã©ããïŒã§ã¯316mgïŒKgã§
ããïŒè ¹èå é©çšïŒããŠã¹ïŒã«ãããŠã¯300mgïŒ
Kgã§ããïŒçµå£æäžïŒããŠã¹ïŒã§ã¯1000mgïŒKgã
ã倧ã§ããã åŒäžãR5ãC2ãC6âã¹ã«ãã¢ã«ãã«åºã§ãã
äžè¬åŒã®ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããªã³
åã³ãã®å¡©ã¯äžè¬ã«ãã匷åã«äœçšãæããããŸ
ãæ¯æ§ã§ã¯ãªãããã®ååç©ã®DL50ã¯ïŒåã®é
èå æäžã«ãããŠãäŸãã°çŽ300ã470mgïŒKgã§ã
ãïŒåŸã€ãŠããããã®ååç©ã¯æšæºèª¿å€ã·ã¯ãã
ã¹ãã¢ãããšåãæ²»çäœçšã瀺ãããã·ã¯ããã¹
ãã¢ããããçŽ20ã50ïŒ äœãæ¥æ§æ¯æ§ã瀺ãïŒã·
ã¯ããã¹ãã¢ããã®ïŒåã®éèå æäžã«ããã
DL50ã¯244mgïŒKgã§ãããïŒããããŠãäŸãã°ã©
ããBDçš®ã®ãªã³ãæ§çœè¡ç L5222ã®å Žåçœè¡
ç æ¥çš®åŸïŒæ¥ç®ã«äžåã®éèå æäžã«ãããŠ
DL50ã¯åŒäžR5ãC2ãC6âã¹ã«ãã€ãã¢ã«ãã«åº
ã§ããåŒã®ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããª
ã³åã³è©²ååç©ã®å¡©ã¯ã·ã¯ããã¹ãã¢ãããšåæ§
1.5mgïŒKgã§ãããã¹ãã©âã¯ã»ãâãªâïŒã©ã
ãïŒSpragueâDaweyâRatteïŒã®ååŠéææ§
ãšã·ãâè ¹æ°Žâèè «ïŒLinie AH13ïŒã«ãããŠã¯
ïŒmgïŒKgã§ããã äžè¬åŒã®ååç©ã®æ¯æ§ã®äžè¬åŒã®ããªåå
ç©ãšã®æ¬çºæã«ããçµã¿åããã«ããæžå°ã¯äŸã
ã°æ¬¡ã®å®éšã«ããéããããïŒ æ¥æ§æ¯æ§ ãã¢ïŒTherïŒèãã°ã«ã³ãã©âã²ã³ã»ãã«ã»
ãšã¯ã¹ããªã¡ã³ãã¬ã³ã»ã¢ã«ããã€ãããã«ãã«
ã·ãŠã³ã°ïŒïŒ§undagen der experimente
en ArzneimitteforschungïŒãMBHåºç瀟
ïŒMBHVeragsgessschaftïŒãã¹ããŠããã¬
ã«ãã1965幎ã«ãã枬å®ã äŸãã°ãéã®NMRIâããŠã¹ïŒ20ã25gïŒã«é
èå åã³è ¹èå æäžããŠïŒâïŒïŒâããããã·â
ãšãã«ã¡ã«ã«ããïŒâã·ã¯ããã¹ãã¢ããïŒP1ïŒ
ã®æ¥æ§æ¯æ§ã次ã®ããã«æž¬å®ããã
ãè¡šã
éèå
ãã®éãã·ã¹ãã€ã³ãççé£å¡©æ°ŽïŒç匵溶液ïŒ
ã«æº¶ããã泚å°ãããæ³šå ¥å®¹éã¯åžžã«20mlïŒKgã§
ãã€ããïŒã·ã¹ãã€ã³æº¶æ¶²ã¯éèå åã³è ¹èå 泚
å°ã®éãç¹ã«æ°ãã補é ããïŒãP1ãåæ§ã«çç
é£å¡©æ°Žäžã«æ°ãã«æº¶ããïŒ0.5ã2.5ïŒ æº¶æ¶²ïŒãã·
ã¹ãã€ã³æ³šå°åŸãã ã¡ã«æ³šå°ããã èšèŒããP1åã³P1ïŒã·ã¹ãã€ã³ïŒP1ïŒã·ã¹ã
ã€ã³ïŒïŒã¢ã«ïŒïŒã¢ã«ïŒã®DL50âå€ã¯äœéïŒKg
ããããããã泚å°å®¹é20mlã«é¢ãããã®ã§ã
ãã泚å°å®¹éã10åïŒ200mlïŒKgïŒã«å¢å ããã
ãšäŸãã°P1ã®DL50ã¯460mgïŒKgã«ãã€P1ïŒã·ã¹ã
ã€ã³ïŒã¢ã«æ¯ïŒïŒïŒïŒã®DL50ã¯1090mgïŒKgïŒP1
ã«æåã«é¢ããŠïŒã«é«ãããããè ¹èå 泚å°ã«ã
ãã泚å°å®¹éãçŽ10åã«ãããšç·æ¯æ§ã¯å°éã®æ³š
å ¥å®¹éã§æž¬å®ãããæ¯æ§ã®54ã68ïŒ ã«æžå°ããã
ãã«äœçšããã ãã§ã«èšèŒããããã«ãããªååç©ã¯P1ã®
è ¹èå 泚å°ã®éã«ãDL50ããã¢ã¯ã¿âïŒïŒ30æ¥èŠ³
å¯ïŒãããã¯ãã¢ã¯ã¿â4.5ïŒ90æ¥èŠ³å¯ïŒã®äžæã«
äœçšãããéèå 泚å°ã«ãããŠã¯æ¯æ§æžå°ã¯æ³šå ¥
æéã«ãäŸåãããããããŠãæ³šå ¥æéãïŒåé
ã§ããã°ãP1ïŒïŒåã¢ã«éã·ã¹ãã€ã³ã®DL50ã¯
600mgïŒKgã§ãããè¿ éãªæ³šå ¥ïŒïŒåæäžïŒã®å Ž
åã¯330mgïŒKgã«äžãããP1èªäœã®DL50ã¯290
mgïŒKgã§ãããããªãã¡ãã·ã¹ãã€ã³ã®æ¯æ§æžå°
åäœçšã¯éèå 泚å°ã«ãããŠã¯ããé·ãïŒãã€ã
ããšããïŒæ³šå°æéïŒïŒåéããé·ãïŒã«ãããŠ
ã®ã¿çããã P1åã³ã·ã¹ãã€ã³ã®è ¹èå 泚å°ã®åŸãããŠã¹
ã«ãããŠã¯è ¹è ã®æå·åã¯ç çåŠçãªå€åãèè
现èã®å€åœ¢åã³ã°ãªã³âã²ã³æ倱åã¯è¡ç®¡ç Žå£
ïŒäŸãã°è ¹èäžåèïŒã¯èŠ³å¯ãããªãã äžè¬åŒã®ååç©ã®æ¯æ§ã®æžå°ã¯äžè¬åŒã®ã
ãªååç©ã®åéãäžæããã«ã€ãæžå°ãããæ¯ä¿
è·å¹æã¯æ··åæ¯ã®äœãç¯å²ã§ãäŸãã°ååç©
ïŒã¢ã«éééšã®ç¯å²ã«ãããŠåŒã®ããªååç©ïŒ
ã¢ã«éééšãŸã§ãæã匷ããåŒãç¶ãç¯å²ïŒåå
ç© ïŒã¢ã«éééšãããããªååç©ïŒã10ã¢
ã«éééšïŒã§ã¯æ¯æ§ã®æžå°ã¯æ¯èŒçãã€ããã§ã
ãã äºæ ¢æ§æ¯æ§ ïŒâïŒïŒâããããã·âãšãã«ã¡ã«ã«ããïŒâã·
ã¯ããã¹ãã¢ããïŒP1ïŒïŒã·ã¹ãã€ã³ïŒã¢ã«æ¯
ïŒïŒïŒïŒãNMRIâãããŠã¹ã ãã®çµã¿åããã®DL50ã®53ïŒ ã«çžå¿ãããã
ãããP1383mgïŒKgïŒã·ã¹ãã€ã³685mgïŒKgïŒæ°Ž
溶液20mlïŒKgïŒãäžé±éééããããŠè ¹èå 泚å°
ãããšãïŒåã®æ³šå°ã®åŸïŒå¹ã®ãã¡ã®ïŒå¹ã®åç©
ãæ»äº¡ããããã®éãå šäœã§P16.8ããªã¢ã«ïŒKg
ïŒã·ã¹ãã€ã³34ããªã¢ã«ïŒKgã泚å°ãããåãæ¹
æ³ã§ã·ã¯ããã¹ãã¢ããïŒã·ã¹ãã€ã³ãªãïŒãæ
äžãããšãããšãã°ãã§ã«å šæäžéïŒããªã¢ã«ïŒ
Kgã§ïŒå¹ã®ããŠã¹ãæ»ãã ã P1ïŒã·ã¹ãã€ã³ïŒã¢ã«æ¯ïŒïŒïŒïŒïŒç¬ïŒP130
mgïŒKgïŒã·ã¹ãã€ã³54mgïŒïŒïŒïŒã¢ã«ïŒãæ¯é±é
èå 泚å°ïŒæ°Žæº¶æ¶²ïŒmlïŒKgç¬ïŒ å šã掻åæ§ã®åŠšå®³ã¯ãªãããããã«ééã®æžå°
ãã¿ããããïŒé±éåŸã«ãå šæäžéP1120mgïŒKg
ïŒã·ã¹ãã€ã³216mgïŒKgã§åç©ã殺ãã解åïŒè
çŒã«ããæèŠã¯å šããªããç¹ã«èè±çã瀺åãã
ãã®ã¯å šããªããè¡äžã®ãªã³ã现èåã³è¡å°æ¿ã®
ããããªæžå°ã å±ææ¯æ§ 家å âèè±ïŒP1ïŒã·ã¹ãã€ã³ïŒïŒïŒã¢ã«ïŒïŒé
ã®å®¶å âéçš®ïŒçŽäœéïŒKgïŒã®èè±äžã«èžçæ°Ž25
mläžã®P11.35gïŒã·ã¹ãã€ã³2.42gïŒæº¶è§£æ§éçïŒ
ã30åéã®éïŒåå±æçæäžãè¡ãªãïŒã«ãâã
ã«ãçšããŠäžå®ã®æéåšç®¡ã«æ¶²äœãå°å ¥ããïŒïŒ
æéïŒ30åéãå±æçæäžåŸïŒæ¥ã®çµç¹åŠçæ
èŠïŒèè±çã®æãããªåŸ®åã瀺ããªãç®ã ããªã
èè±ç²èãåç©ã¯å±æé©çšã®åŸæŽã«10ã±æçåã
ãã ãã©ãŠã³âãã¢ã¹çïŒBrownâPearceâ
SarcomenïŒã移æ€ããéã®å®¶å ã®èè±ã«ïŒæ¥ã
ãã«ïŒåå±æé©çšãè¡ãªãïŒãã®ããšä»¥å€ã¯åèš
ãšåæ§ã«è¡ãªããèçŒã«ããå±ææ¯æ§ïŒããããª
èè±å£ã®è¥ååãåºè¡ãªãããããã«å£çœåœ¢åŒã
ã¿ããããåã¯å šãã¿ãããªããçµç¹åŠçïŒéåžž
ã®å°¿è·¯äžç®ã®ç¯å²ã«è «ç移æ€ä»¥å€ã«ã¯å°¿è·¯äžç®ã¯
åºãç¯å²ã§å®å šã§ããããšããã©ãããããã«æµ®
è «æ§åã³ççæ§ã®æå·ãèªããããã æ¯æ¥ïŒåïŒæ¥éå±æé©çšãè¡ãããã®ä»ã¯åèš
ãšåæ§ã§ãããèçŒæèŠïŒåºè¡ã䌎ãè¥ååãã
èè±å£åã³ãããã«å£çœåœ¢æãçµç¹åŠçïŒéåžžã«
ããããªå°¿è·¯äžç®ãååšããèè±å£ã¯æµ®è «ççæ§
ã«å€åããŠããã ç¬ã®èè±ïŒäœéçŽ15Kgã®éã®ãâã°ã«ïŒç¬ïŒã«
èžçæ°Ž50mläžã®P12.7gïŒã·ã¹ãã€ã³4.84gã®æº¶æ¶²
50mlã宀枩ã§æ³šå ¥ãããæ»çæéïŒ30åã现è蚺
æåŠçæèŠïŒããããå±æé©çšã®ïŒé±éåŸïŒèè±
ç²èã¯ãã ãããèè±çã®åŸ®åã¯ãªããïŒã±æ
åŸãå±æé©çšãããè¿ããå±æé©çšã®ïŒé±éåŸã®
现è蚺æåŠïŒãã ããªãèè±ç²èãèè±çã®åŸŽå
ã¯ãªãã æ¬çºæã«ããçµã¿åããåã³äžè¬åŒã®ïŒâã¹
ã«ãã€ãâãªããµã¶ãã¹ããªã³ã®è¬çäœçšã¯äŸã
ã°æ¬¡ã®å®éšããæããã§ããïŒ å±æïŒè å ïŒååŠçæ³ ïœ ããŠã¹ã§ã®çœè¡ç ïŒL1210âçœè¡ç â现èïŒ
ã«ãããŠïŒ ããŠã¹ïŒDBA2ïŒHanâ*ãããã¯è «çç 究
ã«ãããå®éšç®çã«äœ¿çšãããäžå®ã®ããŠã¹çš®
ã®éããŠã¹ã§ãããäŸãã°ããâãã¢âã®
Zentrainstitut fur Versuchstierforschung
ã«ãããŠé£Œè²ãããŠããïŒïŒå¹ãããL1210çœ
è¡ç 现èïŒÃ105ãæ¥çš®ããåŸ0.5æéåŸã«P1
ïŒæ²»çé68mgïŒKgïŒãããã¯P1ïŒã·ã¹ãã€ã³
ïŒã¢ã«æ¯ïŒïŒïŒïŒãïŒåè ¹èå 泚å°ããããšã«
ããæ²»çãããã·ã¹ãã€ã³ãšçµã¿åãããããš
ã«ãã€ãŠP1ã®æ²»çéã¯90mgïŒKgã§ãã€ããæ²»
çåTI50ïŒDL50ãšDC50ããã®åïŒã¯P1åç¬ã§ã¯
3.5ã§ãããããã«å¯ŸããŠP1ïŒã·ã¹ãã€ã³ã¯7.3
ã§ãããããããççé£å¡©æº¶æ¶²ã䜿çšããïŒæº¶
液20mlïŒKgããŠã¹ïŒãæ³šå ¥æéã¯åžžã«ïŒåãã
çããã€ãã ïœ è ¹æ°ŽåïŒNMRIâããŠã¹ïŒäžã®S180èè «ïŒ ããŠã¹ïŒå¹ããã106è «ç现èã移æ€åŸïŒæ¥
ççé£å¡©æº¶æ¶²äžã®P1ãããã¯P1ïŒã·ã¹ãã€ã³
ïŒã¢ã«æ¯ïŒïŒïŒïŒããŠã¹Kgããã10mlïŒãïŒå
ã§è ¹èå 泚å°ïŒæ³šå ¥æéã¯ïŒåããçããïŒã
ãããšã«ããæ²»çãP1åç¬ã§ã¯DC50ã¯18mgïŒ
KgïŒP1ïŒã·ã¹ãã€ã³ïŒã¢ã«æ¯ïŒïŒïŒïŒã§ã¯32
mgïŒKgã§ãããP1ã«çžå¿ããTI50âå€ã¯èŠ³å¯
æé30æ¥ã®å Žå13ã§ã芳å¯æé60æ¥ã®å Žå9.7
ã§ããïŒããã«å¯ŸãçµåãP1ïŒã·ã¹ãã€ã³
ïŒã¢ã«æ¯ïŒïŒïŒïŒã®å Žå芳å¯æé60æ¥ã§23ã§ã
ã€ããäž¡æ¹ã®è «çã«ãããŠã·ã¹ãã€ã³ã®æ·»å ã«
ããæ²»çåã¯çŽïŒåã«éããããã ïœ å®¶å ã®èè±äžã®ãã©ãŠã³âãã¢ã¹èè «ïŒ å®¶å âéçš®ã«ãã©ãŠã³âãã¢ã¹èè «ã®çŽ°èçŽ
107ãç²èäžçµç¹ïŒç²èã®äžã®çŽ°èå±€ïŒäžã«ç§»
æ€ãããè «ç移æ€ïŒæ¥åŸã«37âã®èžçæ°Ž25mläž
ã®P1160ããªã¢ã«ïŒã·ã¹ãã€ã³800ããªã¢ã«
ïŒã¢ã«æ¯ïŒïŒïŒïŒãçšããŠã®å±æé©çšã30ã60
åéè¡ãªãããšã«ããè å ååŠçæ³ãéå§ã
ããããããïŒæ¥ããã§å šäœã§ïŒåç¹°ãè¿ãã èè±å£ã®çµç¹çŽ°çã¯è «çã倧ããªè¡šé¢ã®å£çœå
ã§æããã«åå¿ããŠããããšã瀺ããè «ç移æ€ã®
åšå²ããã®å£çœãæªåŠçã®ã³ã³ããâã«ã®èªç¶ãª
äžå€®ã«ããå£çœãšç°ãªãç¹åŸŽçã§ãããè «çã®å€§
ããã¯çŽåŸïŒã25mmã§ãã€ããå®éšã®çµããã«ã¯
å ç®çŽ°èã¯çµç¹åŠçãªå€åãªãã«è «çãæããª
ãã èžç·æ圢ãâãâããŠã¹ïŒnuïŒnuâMauseãïŒ
å ç«é²åŸ¡ãçºçåŠçã«æããªã裞ããŠã¹ïŒã«é¢ã
ãäººè «ç现èïŒè «çç°ç©ç§»æ€ãå®éšåç©ã«äººè «ç
现èïŒã§ã®ç³»çµ±çååŠçæ³ïŒäœçšç©è³ªã身äœäžã«
è¡ç®¡ãä»ããŠå°å ¥ããïŒã ïŒãã®å®éšã¯PovsenïŒC.O.ãJacobsenïŒG.
K.ãRygaardïŒJ.èãThe Laboratory Anima
in Drug TestingãEditor A.Spiegeã第
63ã73é ãFischeråºç瀟ãã¹ããŠãã¬ã«ãã
1973幎ã«ããå®æœïŒã ïœ ç£å©Šäººç§ã®æè¡æåºç©ãã人ã®ä¹³çãèžç·æ
圢ãâãâããŠã¹ã«ç°çš®é移æ€ãè¡ãªã€ããå
ç©ã®ä¹³çªèµ·äžã«çŽåŸïŒã10mmã®ãããåçã移
æ€ããããšã«ãã23ã25åç©äœééåŸã移æ€ç©
ã0.15ã0.25gã«æé·ããåŸæ²»çãè¡ãªããè «
çé¢ç©ã®æž¬å®ã«ããæ²»çå¹æã枬å®ããã ããŠã¹ïŒKgãããP198mgïŒã·ã¹ãã€ã³176mg
ã®æ°Žæº¶æ¶²10mlãïŒåè ¹èå 泚å°ïŒæ³šå ¥æéã¯ïŒ
åããçïŒããåŸãæªåŠçã®ã³ã³ããâã«ã«ã
ãã¹ãŠè «çã®æé·ã¯ããããã«æå¶ããããæ°Ž
溶液ïŒããŠã¹ïŒKgããã10mlïŒã®P1296mgïŒKg
ïŒã·ã¹ãã€ã³535mgïŒKgïŒDL50ã®çŽ40ïŒ ã«çžå¿
ããïŒã®ïŒåã®è ¹èå 泚å°ïŒïŒåããçïŒã¯è «
çã®æé·ãæå¶ãããã®æå¶ã¯æšæºæ¯èŒç©è³ªãš
ããŠã®ççé£å¡©æº¶æ¶²ïŒ10mlïŒKgããŠã¹ïŒäžã®ã·
ã¯ããã¹ãã¢ãã100mgïŒKgã®ïŒåã®æ³šå°ã§é
ããããæå¶ã«çžå¿ããäžæ¹æªåŠçã®ã³ã³ãã
âã«ã¯åã芳å¯æéïŒïŒé±éïŒã«çžå¿ããå²å
ã®ééå¢å ã䌎ãªãïŒåã®è «çè¡šé¢ç©ã«ãªã€
ãã ããããP1250mlïŒKgïŒã·ã¹ãã€ã³450mgïŒ
KgïŒããŠã¹ïŒKgããããããã氎溶液10mlïŒã
ïŒé±éã«ïŒåºŠæ°å泚å°ããå ŽåïŒæ³šå ¥æéã¯ïŒ
åããçããïŒãçã®æ²»çãšããæå³ã«ãããŠ
è «çéã®æžå°ãéãããããã®æ²»çã¯ã·ã¯ãã
ã¹ãã¢ãã150mgïŒKgãåæ§ã«ïŒé±ïŒå泚å°ã
ãéã®äœçšã«çžå¿ãããæªåŠçã®ã³ã³ããâã«
ã¯ïŒé±éã®èŠ³å¯æéå ã«è «çã§æ»äº¡ããã ããããªãããP1ãã·ã¹ãã€ã³ãšçµã¿åã
ããïŒäºæ ¢æ§ïŒæ¯æ§äœçšã¯ãã®äœ¿çšã®éã«ã·ã¯
ããã¹ãã¢ããã®æ¯æ§äœçšããæããã«å°ã
ãããã®ããšã¯åŠçåç©ã®èããè¯ãäžè¬çç¶
æ ã«ããèªãšããããã ïœ ãâãâããŠã¹ã§ã®äººè§åèè±çïŒ æ³å°¿åšç§ã®ç é¢ã®æè¡æåºç©ããã®ååŠçæ³
æµææ§ã®å¥³æ§ã®è§åèè±çã第ïŒåç©äœéé
åŸãéã®ãâãâããŠã¹ã«ç§»æ€ããã系統çå
åŠçæ³ã¯P1250mgïŒKgïŒïŒ0.74ããªã¢ã«ïŒKgã
ãŠã¹ïŒïŒã·ã¹ãã€ã³449mgïŒKgïŒæ°Žæº¶æ¶²ïŒ10mlïŒ
KgããŠã¹ïŒãïŒåšïŒåºŠïŒåè ¹èå 泚å°ããããš
ã«ããããããã¯åãééã§ã·ã¯ããã¹ãã¢ã
ãïŒ150mgïŒKgïŒ0.53ããªã¢ã«ïŒKgïŒãïŒåè ¹
èå 泚å°ããããšã«ããè¡ãªããããå®éšéå§
18æ¥åŸã«æ»äº¡ããã³ã³ããâã«ã«èŒã¹P1ïŒïŒ
åã¢ã«éã·ã¹ãã€ã³ã¯ç¹°ãè¿ãã®äœ¿çšã«ãããŠ
è «çå¢å€§ã®éæ¢åã³åç©ã®çåã«äœçšãããå¶
çäœçšã¯æšæºæ¯èŒç©è³ªãšããŠã®ã·ã¯ããã¹ãã¢
ããã150mgïŒKgã®æäžéïŒïŒïŒïŒã¢ã«åœéã«çž åœïŒã§äœ¿çšããå Žåã«çžå¿ããã åé¢ããåè¢çæµã¯åè¢ã®æªæ§è «çã®çŽ°èéæ¢
åŠçœ®æ³ã§ããããã®éä»ã®åšå®ã¯çŽ°èéæ¢å€ã®äœ
çšã«ãããããªãã è «çãæããïŒãšã·ãèè «ïŒã©ããã®èã®åé¢
çæµããã®æ¹æ³ã®åç©ã¢ãã«ãšããŠäœ¿çšãããã
ã®é空çæµããã³çŽ°èéæ¢å€çæµã«ããè «çå¢å€§
ã枬å®ããã P1ïŒ5000nmoïŒmlïŒïŒã·ã¹ãã€ã³ïŒïŒåã¢ã«
éïŒã§20åéçæµããåŸãåç©ã®å®å šãªæ²»çãé
ããããåæã«10000nmoïŒmlã®æº¶æ¶²ãçšããŠ
ã®çæµã«ãããŠãéããããããã®åç©ã¯å®éšåŸ
å幎ãã€ãŠãåçºããªãã€ãã P1åç¬ã§ã®çæµã¯ããŸãå¹æã¯ãªãã€ãã
5000nmoïŒmlã§ã¯ãçæµåŸãåç©ã¯æ»ãã ã
2000nmoïŒmlã§ã¯åç©ïŒå¹äžã®ïŒå¹ãŸã§ãè «ç
å¢å€§ã®æå¶ãšå ±ã«æ²»çã芳å¯ãããã äžè¬åŒã®ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããª
ã³åã³ïŒåã¯äžè¬åŒã®ããªååç©ãå«æããå»
è¬èª¿å€ã®è£œé ã¯äžè¬ã«å ¬ç¥ã®æ¹æ³ã§è¡ãªããã
çš®ã ã®æ³šå°æº¶æ¶²ã®äŸã«ã€ããŠæ¬¡ã«è©³èª¬ããïŒ äŸ ïŒ äœçšç©è³ªãšããŠïŒâïŒïŒâããããã·âãšãã«
ã¡ã«ã«ããïŒâã·ã¯ããã¹ãã¢ããïŒR1ïŒ50mg
ïŒïŒ0.15ããªã¢ã«ïŒåã³ç©è³ªP1ã«å¯Ÿãçš®ã ã®ã¢ã«
æ¯ïŒïŒåãïŒååã³10åïŒã§ïŒ¬âã·ã¹ãã€ã³ã次
ã®ããã«å«æããçµã¿åãã調å€ïŒ ïŒ æ³šå°ç¶ã¯æ¬¡ã®ãã®ãå«æããïŒ
ãã®éãã·ã¹ãã€ã³ãççé£å¡©æ°ŽïŒç匵溶液ïŒ
ã«æº¶ããã泚å°ãããæ³šå ¥å®¹éã¯åžžã«20mlïŒKgã§
ãã€ããïŒã·ã¹ãã€ã³æº¶æ¶²ã¯éèå åã³è ¹èå 泚
å°ã®éãç¹ã«æ°ãã補é ããïŒãP1ãåæ§ã«çç
é£å¡©æ°Žäžã«æ°ãã«æº¶ããïŒ0.5ã2.5ïŒ æº¶æ¶²ïŒãã·
ã¹ãã€ã³æ³šå°åŸãã ã¡ã«æ³šå°ããã èšèŒããP1åã³P1ïŒã·ã¹ãã€ã³ïŒP1ïŒã·ã¹ã
ã€ã³ïŒïŒã¢ã«ïŒïŒã¢ã«ïŒã®DL50âå€ã¯äœéïŒKg
ããããããã泚å°å®¹é20mlã«é¢ãããã®ã§ã
ãã泚å°å®¹éã10åïŒ200mlïŒKgïŒã«å¢å ããã
ãšäŸãã°P1ã®DL50ã¯460mgïŒKgã«ãã€P1ïŒã·ã¹ã
ã€ã³ïŒã¢ã«æ¯ïŒïŒïŒïŒã®DL50ã¯1090mgïŒKgïŒP1
ã«æåã«é¢ããŠïŒã«é«ãããããè ¹èå 泚å°ã«ã
ãã泚å°å®¹éãçŽ10åã«ãããšç·æ¯æ§ã¯å°éã®æ³š
å ¥å®¹éã§æž¬å®ãããæ¯æ§ã®54ã68ïŒ ã«æžå°ããã
ãã«äœçšããã ãã§ã«èšèŒããããã«ãããªååç©ã¯P1ã®
è ¹èå 泚å°ã®éã«ãDL50ããã¢ã¯ã¿âïŒïŒ30æ¥èŠ³
å¯ïŒãããã¯ãã¢ã¯ã¿â4.5ïŒ90æ¥èŠ³å¯ïŒã®äžæã«
äœçšãããéèå 泚å°ã«ãããŠã¯æ¯æ§æžå°ã¯æ³šå ¥
æéã«ãäŸåãããããããŠãæ³šå ¥æéãïŒåé
ã§ããã°ãP1ïŒïŒåã¢ã«éã·ã¹ãã€ã³ã®DL50ã¯
600mgïŒKgã§ãããè¿ éãªæ³šå ¥ïŒïŒåæäžïŒã®å Ž
åã¯330mgïŒKgã«äžãããP1èªäœã®DL50ã¯290
mgïŒKgã§ãããããªãã¡ãã·ã¹ãã€ã³ã®æ¯æ§æžå°
åäœçšã¯éèå 泚å°ã«ãããŠã¯ããé·ãïŒãã€ã
ããšããïŒæ³šå°æéïŒïŒåéããé·ãïŒã«ãããŠ
ã®ã¿çããã P1åã³ã·ã¹ãã€ã³ã®è ¹èå 泚å°ã®åŸãããŠã¹
ã«ãããŠã¯è ¹è ã®æå·åã¯ç çåŠçãªå€åãèè
现èã®å€åœ¢åã³ã°ãªã³âã²ã³æ倱åã¯è¡ç®¡ç Žå£
ïŒäŸãã°è ¹èäžåèïŒã¯èŠ³å¯ãããªãã äžè¬åŒã®ååç©ã®æ¯æ§ã®æžå°ã¯äžè¬åŒã®ã
ãªååç©ã®åéãäžæããã«ã€ãæžå°ãããæ¯ä¿
è·å¹æã¯æ··åæ¯ã®äœãç¯å²ã§ãäŸãã°ååç©
ïŒã¢ã«éééšã®ç¯å²ã«ãããŠåŒã®ããªååç©ïŒ
ã¢ã«éééšãŸã§ãæã匷ããåŒãç¶ãç¯å²ïŒåå
ç© ïŒã¢ã«éééšãããããªååç©ïŒã10ã¢
ã«éééšïŒã§ã¯æ¯æ§ã®æžå°ã¯æ¯èŒçãã€ããã§ã
ãã äºæ ¢æ§æ¯æ§ ïŒâïŒïŒâããããã·âãšãã«ã¡ã«ã«ããïŒâã·
ã¯ããã¹ãã¢ããïŒP1ïŒïŒã·ã¹ãã€ã³ïŒã¢ã«æ¯
ïŒïŒïŒïŒãNMRIâãããŠã¹ã ãã®çµã¿åããã®DL50ã®53ïŒ ã«çžå¿ãããã
ãããP1383mgïŒKgïŒã·ã¹ãã€ã³685mgïŒKgïŒæ°Ž
溶液20mlïŒKgïŒãäžé±éééããããŠè ¹èå 泚å°
ãããšãïŒåã®æ³šå°ã®åŸïŒå¹ã®ãã¡ã®ïŒå¹ã®åç©
ãæ»äº¡ããããã®éãå šäœã§P16.8ããªã¢ã«ïŒKg
ïŒã·ã¹ãã€ã³34ããªã¢ã«ïŒKgã泚å°ãããåãæ¹
æ³ã§ã·ã¯ããã¹ãã¢ããïŒã·ã¹ãã€ã³ãªãïŒãæ
äžãããšãããšãã°ãã§ã«å šæäžéïŒããªã¢ã«ïŒ
Kgã§ïŒå¹ã®ããŠã¹ãæ»ãã ã P1ïŒã·ã¹ãã€ã³ïŒã¢ã«æ¯ïŒïŒïŒïŒïŒç¬ïŒP130
mgïŒKgïŒã·ã¹ãã€ã³54mgïŒïŒïŒïŒã¢ã«ïŒãæ¯é±é
èå 泚å°ïŒæ°Žæº¶æ¶²ïŒmlïŒKgç¬ïŒ å šã掻åæ§ã®åŠšå®³ã¯ãªãããããã«ééã®æžå°
ãã¿ããããïŒé±éåŸã«ãå šæäžéP1120mgïŒKg
ïŒã·ã¹ãã€ã³216mgïŒKgã§åç©ã殺ãã解åïŒè
çŒã«ããæèŠã¯å šããªããç¹ã«èè±çã瀺åãã
ãã®ã¯å šããªããè¡äžã®ãªã³ã现èåã³è¡å°æ¿ã®
ããããªæžå°ã å±ææ¯æ§ 家å âèè±ïŒP1ïŒã·ã¹ãã€ã³ïŒïŒïŒã¢ã«ïŒïŒé
ã®å®¶å âéçš®ïŒçŽäœéïŒKgïŒã®èè±äžã«èžçæ°Ž25
mläžã®P11.35gïŒã·ã¹ãã€ã³2.42gïŒæº¶è§£æ§éçïŒ
ã30åéã®éïŒåå±æçæäžãè¡ãªãïŒã«ãâã
ã«ãçšããŠäžå®ã®æéåšç®¡ã«æ¶²äœãå°å ¥ããïŒïŒ
æéïŒ30åéãå±æçæäžåŸïŒæ¥ã®çµç¹åŠçæ
èŠïŒèè±çã®æãããªåŸ®åã瀺ããªãç®ã ããªã
èè±ç²èãåç©ã¯å±æé©çšã®åŸæŽã«10ã±æçåã
ãã ãã©ãŠã³âãã¢ã¹çïŒBrownâPearceâ
SarcomenïŒã移æ€ããéã®å®¶å ã®èè±ã«ïŒæ¥ã
ãã«ïŒåå±æé©çšãè¡ãªãïŒãã®ããšä»¥å€ã¯åèš
ãšåæ§ã«è¡ãªããèçŒã«ããå±ææ¯æ§ïŒããããª
èè±å£ã®è¥ååãåºè¡ãªãããããã«å£çœåœ¢åŒã
ã¿ããããåã¯å šãã¿ãããªããçµç¹åŠçïŒéåžž
ã®å°¿è·¯äžç®ã®ç¯å²ã«è «ç移æ€ä»¥å€ã«ã¯å°¿è·¯äžç®ã¯
åºãç¯å²ã§å®å šã§ããããšããã©ãããããã«æµ®
è «æ§åã³ççæ§ã®æå·ãèªããããã æ¯æ¥ïŒåïŒæ¥éå±æé©çšãè¡ãããã®ä»ã¯åèš
ãšåæ§ã§ãããèçŒæèŠïŒåºè¡ã䌎ãè¥ååãã
èè±å£åã³ãããã«å£çœåœ¢æãçµç¹åŠçïŒéåžžã«
ããããªå°¿è·¯äžç®ãååšããèè±å£ã¯æµ®è «ççæ§
ã«å€åããŠããã ç¬ã®èè±ïŒäœéçŽ15Kgã®éã®ãâã°ã«ïŒç¬ïŒã«
èžçæ°Ž50mläžã®P12.7gïŒã·ã¹ãã€ã³4.84gã®æº¶æ¶²
50mlã宀枩ã§æ³šå ¥ãããæ»çæéïŒ30åã现è蚺
æåŠçæèŠïŒããããå±æé©çšã®ïŒé±éåŸïŒèè±
ç²èã¯ãã ãããèè±çã®åŸ®åã¯ãªããïŒã±æ
åŸãå±æé©çšãããè¿ããå±æé©çšã®ïŒé±éåŸã®
现è蚺æåŠïŒãã ããªãèè±ç²èãèè±çã®åŸŽå
ã¯ãªãã æ¬çºæã«ããçµã¿åããåã³äžè¬åŒã®ïŒâã¹
ã«ãã€ãâãªããµã¶ãã¹ããªã³ã®è¬çäœçšã¯äŸã
ã°æ¬¡ã®å®éšããæããã§ããïŒ å±æïŒè å ïŒååŠçæ³ ïœ ããŠã¹ã§ã®çœè¡ç ïŒL1210âçœè¡ç â现èïŒ
ã«ãããŠïŒ ããŠã¹ïŒDBA2ïŒHanâ*ãããã¯è «çç 究
ã«ãããå®éšç®çã«äœ¿çšãããäžå®ã®ããŠã¹çš®
ã®éããŠã¹ã§ãããäŸãã°ããâãã¢âã®
Zentrainstitut fur Versuchstierforschung
ã«ãããŠé£Œè²ãããŠããïŒïŒå¹ãããL1210çœ
è¡ç 现èïŒÃ105ãæ¥çš®ããåŸ0.5æéåŸã«P1
ïŒæ²»çé68mgïŒKgïŒãããã¯P1ïŒã·ã¹ãã€ã³
ïŒã¢ã«æ¯ïŒïŒïŒïŒãïŒåè ¹èå 泚å°ããããšã«
ããæ²»çãããã·ã¹ãã€ã³ãšçµã¿åãããããš
ã«ãã€ãŠP1ã®æ²»çéã¯90mgïŒKgã§ãã€ããæ²»
çåTI50ïŒDL50ãšDC50ããã®åïŒã¯P1åç¬ã§ã¯
3.5ã§ãããããã«å¯ŸããŠP1ïŒã·ã¹ãã€ã³ã¯7.3
ã§ãããããããççé£å¡©æº¶æ¶²ã䜿çšããïŒæº¶
液20mlïŒKgããŠã¹ïŒãæ³šå ¥æéã¯åžžã«ïŒåãã
çããã€ãã ïœ è ¹æ°ŽåïŒNMRIâããŠã¹ïŒäžã®S180èè «ïŒ ããŠã¹ïŒå¹ããã106è «ç现èã移æ€åŸïŒæ¥
ççé£å¡©æº¶æ¶²äžã®P1ãããã¯P1ïŒã·ã¹ãã€ã³
ïŒã¢ã«æ¯ïŒïŒïŒïŒããŠã¹Kgããã10mlïŒãïŒå
ã§è ¹èå 泚å°ïŒæ³šå ¥æéã¯ïŒåããçããïŒã
ãããšã«ããæ²»çãP1åç¬ã§ã¯DC50ã¯18mgïŒ
KgïŒP1ïŒã·ã¹ãã€ã³ïŒã¢ã«æ¯ïŒïŒïŒïŒã§ã¯32
mgïŒKgã§ãããP1ã«çžå¿ããTI50âå€ã¯èŠ³å¯
æé30æ¥ã®å Žå13ã§ã芳å¯æé60æ¥ã®å Žå9.7
ã§ããïŒããã«å¯ŸãçµåãP1ïŒã·ã¹ãã€ã³
ïŒã¢ã«æ¯ïŒïŒïŒïŒã®å Žå芳å¯æé60æ¥ã§23ã§ã
ã€ããäž¡æ¹ã®è «çã«ãããŠã·ã¹ãã€ã³ã®æ·»å ã«
ããæ²»çåã¯çŽïŒåã«éããããã ïœ å®¶å ã®èè±äžã®ãã©ãŠã³âãã¢ã¹èè «ïŒ å®¶å âéçš®ã«ãã©ãŠã³âãã¢ã¹èè «ã®çŽ°èçŽ
107ãç²èäžçµç¹ïŒç²èã®äžã®çŽ°èå±€ïŒäžã«ç§»
æ€ãããè «ç移æ€ïŒæ¥åŸã«37âã®èžçæ°Ž25mläž
ã®P1160ããªã¢ã«ïŒã·ã¹ãã€ã³800ããªã¢ã«
ïŒã¢ã«æ¯ïŒïŒïŒïŒãçšããŠã®å±æé©çšã30ã60
åéè¡ãªãããšã«ããè å ååŠçæ³ãéå§ã
ããããããïŒæ¥ããã§å šäœã§ïŒåç¹°ãè¿ãã èè±å£ã®çµç¹çŽ°çã¯è «çã倧ããªè¡šé¢ã®å£çœå
ã§æããã«åå¿ããŠããããšã瀺ããè «ç移æ€ã®
åšå²ããã®å£çœãæªåŠçã®ã³ã³ããâã«ã®èªç¶ãª
äžå€®ã«ããå£çœãšç°ãªãç¹åŸŽçã§ãããè «çã®å€§
ããã¯çŽåŸïŒã25mmã§ãã€ããå®éšã®çµããã«ã¯
å ç®çŽ°èã¯çµç¹åŠçãªå€åãªãã«è «çãæããª
ãã èžç·æ圢ãâãâããŠã¹ïŒnuïŒnuâMauseãïŒ
å ç«é²åŸ¡ãçºçåŠçã«æããªã裞ããŠã¹ïŒã«é¢ã
ãäººè «ç现èïŒè «çç°ç©ç§»æ€ãå®éšåç©ã«äººè «ç
现èïŒã§ã®ç³»çµ±çååŠçæ³ïŒäœçšç©è³ªã身äœäžã«
è¡ç®¡ãä»ããŠå°å ¥ããïŒã ïŒãã®å®éšã¯PovsenïŒC.O.ãJacobsenïŒG.
K.ãRygaardïŒJ.èãThe Laboratory Anima
in Drug TestingãEditor A.Spiegeã第
63ã73é ãFischeråºç瀟ãã¹ããŠãã¬ã«ãã
1973幎ã«ããå®æœïŒã ïœ ç£å©Šäººç§ã®æè¡æåºç©ãã人ã®ä¹³çãèžç·æ
圢ãâãâããŠã¹ã«ç°çš®é移æ€ãè¡ãªã€ããå
ç©ã®ä¹³çªèµ·äžã«çŽåŸïŒã10mmã®ãããåçã移
æ€ããããšã«ãã23ã25åç©äœééåŸã移æ€ç©
ã0.15ã0.25gã«æé·ããåŸæ²»çãè¡ãªããè «
çé¢ç©ã®æž¬å®ã«ããæ²»çå¹æã枬å®ããã ããŠã¹ïŒKgãããP198mgïŒã·ã¹ãã€ã³176mg
ã®æ°Žæº¶æ¶²10mlãïŒåè ¹èå 泚å°ïŒæ³šå ¥æéã¯ïŒ
åããçïŒããåŸãæªåŠçã®ã³ã³ããâã«ã«ã
ãã¹ãŠè «çã®æé·ã¯ããããã«æå¶ããããæ°Ž
溶液ïŒããŠã¹ïŒKgããã10mlïŒã®P1296mgïŒKg
ïŒã·ã¹ãã€ã³535mgïŒKgïŒDL50ã®çŽ40ïŒ ã«çžå¿
ããïŒã®ïŒåã®è ¹èå 泚å°ïŒïŒåããçïŒã¯è «
çã®æé·ãæå¶ãããã®æå¶ã¯æšæºæ¯èŒç©è³ªãš
ããŠã®ççé£å¡©æº¶æ¶²ïŒ10mlïŒKgããŠã¹ïŒäžã®ã·
ã¯ããã¹ãã¢ãã100mgïŒKgã®ïŒåã®æ³šå°ã§é
ããããæå¶ã«çžå¿ããäžæ¹æªåŠçã®ã³ã³ãã
âã«ã¯åã芳å¯æéïŒïŒé±éïŒã«çžå¿ããå²å
ã®ééå¢å ã䌎ãªãïŒåã®è «çè¡šé¢ç©ã«ãªã€
ãã ããããP1250mlïŒKgïŒã·ã¹ãã€ã³450mgïŒ
KgïŒããŠã¹ïŒKgããããããã氎溶液10mlïŒã
ïŒé±éã«ïŒåºŠæ°å泚å°ããå ŽåïŒæ³šå ¥æéã¯ïŒ
åããçããïŒãçã®æ²»çãšããæå³ã«ãããŠ
è «çéã®æžå°ãéãããããã®æ²»çã¯ã·ã¯ãã
ã¹ãã¢ãã150mgïŒKgãåæ§ã«ïŒé±ïŒå泚å°ã
ãéã®äœçšã«çžå¿ãããæªåŠçã®ã³ã³ããâã«
ã¯ïŒé±éã®èŠ³å¯æéå ã«è «çã§æ»äº¡ããã ããããªãããP1ãã·ã¹ãã€ã³ãšçµã¿åã
ããïŒäºæ ¢æ§ïŒæ¯æ§äœçšã¯ãã®äœ¿çšã®éã«ã·ã¯
ããã¹ãã¢ããã®æ¯æ§äœçšããæããã«å°ã
ãããã®ããšã¯åŠçåç©ã®èããè¯ãäžè¬çç¶
æ ã«ããèªãšããããã ïœ ãâãâããŠã¹ã§ã®äººè§åèè±çïŒ æ³å°¿åšç§ã®ç é¢ã®æè¡æåºç©ããã®ååŠçæ³
æµææ§ã®å¥³æ§ã®è§åèè±çã第ïŒåç©äœéé
åŸãéã®ãâãâããŠã¹ã«ç§»æ€ããã系統çå
åŠçæ³ã¯P1250mgïŒKgïŒïŒ0.74ããªã¢ã«ïŒKgã
ãŠã¹ïŒïŒã·ã¹ãã€ã³449mgïŒKgïŒæ°Žæº¶æ¶²ïŒ10mlïŒ
KgããŠã¹ïŒãïŒåšïŒåºŠïŒåè ¹èå 泚å°ããããš
ã«ããããããã¯åãééã§ã·ã¯ããã¹ãã¢ã
ãïŒ150mgïŒKgïŒ0.53ããªã¢ã«ïŒKgïŒãïŒåè ¹
èå 泚å°ããããšã«ããè¡ãªããããå®éšéå§
18æ¥åŸã«æ»äº¡ããã³ã³ããâã«ã«èŒã¹P1ïŒïŒ
åã¢ã«éã·ã¹ãã€ã³ã¯ç¹°ãè¿ãã®äœ¿çšã«ãããŠ
è «çå¢å€§ã®éæ¢åã³åç©ã®çåã«äœçšãããå¶
çäœçšã¯æšæºæ¯èŒç©è³ªãšããŠã®ã·ã¯ããã¹ãã¢
ããã150mgïŒKgã®æäžéïŒïŒïŒïŒã¢ã«åœéã«çž åœïŒã§äœ¿çšããå Žåã«çžå¿ããã åé¢ããåè¢çæµã¯åè¢ã®æªæ§è «çã®çŽ°èéæ¢
åŠçœ®æ³ã§ããããã®éä»ã®åšå®ã¯çŽ°èéæ¢å€ã®äœ
çšã«ãããããªãã è «çãæããïŒãšã·ãèè «ïŒã©ããã®èã®åé¢
çæµããã®æ¹æ³ã®åç©ã¢ãã«ãšããŠäœ¿çšãããã
ã®é空çæµããã³çŽ°èéæ¢å€çæµã«ããè «çå¢å€§
ã枬å®ããã P1ïŒ5000nmoïŒmlïŒïŒã·ã¹ãã€ã³ïŒïŒåã¢ã«
éïŒã§20åéçæµããåŸãåç©ã®å®å šãªæ²»çãé
ããããåæã«10000nmoïŒmlã®æº¶æ¶²ãçšããŠ
ã®çæµã«ãããŠãéããããããã®åç©ã¯å®éšåŸ
å幎ãã€ãŠãåçºããªãã€ãã P1åç¬ã§ã®çæµã¯ããŸãå¹æã¯ãªãã€ãã
5000nmoïŒmlã§ã¯ãçæµåŸãåç©ã¯æ»ãã ã
2000nmoïŒmlã§ã¯åç©ïŒå¹äžã®ïŒå¹ãŸã§ãè «ç
å¢å€§ã®æå¶ãšå ±ã«æ²»çã芳å¯ãããã äžè¬åŒã®ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããª
ã³åã³ïŒåã¯äžè¬åŒã®ããªååç©ãå«æããå»
è¬èª¿å€ã®è£œé ã¯äžè¬ã«å ¬ç¥ã®æ¹æ³ã§è¡ãªããã
çš®ã ã®æ³šå°æº¶æ¶²ã®äŸã«ã€ããŠæ¬¡ã«è©³èª¬ããïŒ äŸ ïŒ äœçšç©è³ªãšããŠïŒâïŒïŒâããããã·âãšãã«
ã¡ã«ã«ããïŒâã·ã¯ããã¹ãã¢ããïŒR1ïŒ50mg
ïŒïŒ0.15ããªã¢ã«ïŒåã³ç©è³ªP1ã«å¯Ÿãçš®ã ã®ã¢ã«
æ¯ïŒïŒåãïŒååã³10åïŒã§ïŒ¬âã·ã¹ãã€ã³ã次
ã®ããã«å«æããçµã¿åãã調å€ïŒ ïŒ æ³šå°ç¶ã¯æ¬¡ã®ãã®ãå«æããïŒ
ãè¡šã
ç©è³ªP1ãâã·ã¹ãã€ã³åã³å Žåã«ããå¿
èŠ
ã§ããã°ãâãã³ããããçªçŽ ãå¹ã蟌ã¿ãªã
ããæ°Žã«æº¶ãããïŒml容éã®æº¶æ¶²ãã€ãããå ¬ç¥
æ³ã§æ» èæ¿Ÿéããã次ãã§ããã®æº¶æ¶²ãç¡èæ¡ä»¶
äžã«åçµä¹Ÿç¥çšæ ãæãã10mlè€è²æ³šå°ç¶ã«é é
ããåçµä¹Ÿç¥è£ 眮äžã§åçµä¹Ÿç¥ãããåŒãç¶ãã
åçµä¹Ÿç¥è£ 眮ã«ä¹Ÿç¥çªçŽ ãéããã¢ã³ãã«ç¶ãè£
眮äžã§å¯éããã æäžå¯èœãªæ³šå°æº¶æ¶²ã®è£œé ã®ããã«ã¢ã³ãã«ç¶
ã®å 容ç©ã泚å°çšæ°ŽïŒmläžã«æº¶ããã ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããªã³ãšããª
ååç©ãåé¢ããŠäœ¿çšããããã®èª¿å äŸ ïŒ äŸïŒã«èšèŒããããã«ïŒâïŒïŒâããããã·â
ãšãã«ã¡ã«ã«ããïŒâã·ã¯ããã¹ãã¢ããïŒP1ïŒ
50.0mgïŒ0.15ããªã¢ã«ïŒåã³ïŒ€âãã³ããã250.0
mgãïŒæ³šå°çšïŒæ°Žäžã«æº¶ããã容éïŒmlãšããå
çµä¹Ÿç¥ãããã äŸ ïŒ äŸïŒã«èšèŒããããã«ã·ã¹ãã€ã³36.0mgïŒ0.3
ããªã¢ã«ïŒåã³ïŒ€âãã³ããã220.0mgãïŒæ³šå°
çšïŒæ°Žã«æº¶ãããïŒml溶液ãšããåçµä¹Ÿç¥ãã
ããåæ§ã«ã㊠âã·ã¹ãã€ã³90mgïŒ0.75ããªã¢ã«ïŒåã³ïŒ€â
ãã³ããã140.0mg䞊ã³ã« âã·ã¹ãã€ã³180mgïŒ1.5ããªã¢ã«ïŒïŒãã³ã
ããæ·»å ãªãïŒã ãå«æããã·ã¹ãã€ã³ã®åçµä¹Ÿç¥ã補é ããã 泚å°æº¶æ¶²ã®è£œé ã®ããã«ã¯äŸïŒåã³äŸïŒã«ãã
ã¢ã³ãã«ç¶ã®å 容ç©ãããããïŒæ³šå°çšïŒæ°ŽïŒml
äžã«æº¶è§£ããã äŸ ïŒ äœçšç©è³ªãšããŠâã·ã¯ãããã·ã«ã¢ãã³å¡©â82
mgïŒïŒ0.15ããªã¢ã«ïŒåã³ç©è³ªâã·ã¯ãããã·ã«
ã¢ãã³å¡©âã«å¯Ÿãçš®ã ã®ã¢ã«æ¯ïŒïŒåãïŒååã³
10åïŒã§ïŒ¬âã·ã¹ãã€ã³ã次ã®ããã«å«æããçµ
ã¿åãã調å€ïŒ ã·ã¯ãããã·ã«ã¢ãã³å¡©ïŒïŒâãïŒâïŒãã¹â
ïŒïŒâã¯ãã«ãšãã«ïŒâã¢ããâïŒâãªããœâãã
ã©ãããâ2HâïŒïŒïŒïŒïŒâãªããµã¶ãã¹ããª
ã³âïŒâã€ã«âããªãâïŒâã¡ã«ã«ããâããã
ã³ã¹ã«ãã³é žâã·ã¯ãããã·ã«ã¢ãã³å¡©ã ïŒ æ³šå°ç¶ã¯æ¬¡ã®ãã®ãå«æããïŒ
ã§ããã°ãâãã³ããããçªçŽ ãå¹ã蟌ã¿ãªã
ããæ°Žã«æº¶ãããïŒml容éã®æº¶æ¶²ãã€ãããå ¬ç¥
æ³ã§æ» èæ¿Ÿéããã次ãã§ããã®æº¶æ¶²ãç¡èæ¡ä»¶
äžã«åçµä¹Ÿç¥çšæ ãæãã10mlè€è²æ³šå°ç¶ã«é é
ããåçµä¹Ÿç¥è£ 眮äžã§åçµä¹Ÿç¥ãããåŒãç¶ãã
åçµä¹Ÿç¥è£ 眮ã«ä¹Ÿç¥çªçŽ ãéããã¢ã³ãã«ç¶ãè£
眮äžã§å¯éããã æäžå¯èœãªæ³šå°æº¶æ¶²ã®è£œé ã®ããã«ã¢ã³ãã«ç¶
ã®å 容ç©ã泚å°çšæ°ŽïŒmläžã«æº¶ããã ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããªã³ãšããª
ååç©ãåé¢ããŠäœ¿çšããããã®èª¿å äŸ ïŒ äŸïŒã«èšèŒããããã«ïŒâïŒïŒâããããã·â
ãšãã«ã¡ã«ã«ããïŒâã·ã¯ããã¹ãã¢ããïŒP1ïŒ
50.0mgïŒ0.15ããªã¢ã«ïŒåã³ïŒ€âãã³ããã250.0
mgãïŒæ³šå°çšïŒæ°Žäžã«æº¶ããã容éïŒmlãšããå
çµä¹Ÿç¥ãããã äŸ ïŒ äŸïŒã«èšèŒããããã«ã·ã¹ãã€ã³36.0mgïŒ0.3
ããªã¢ã«ïŒåã³ïŒ€âãã³ããã220.0mgãïŒæ³šå°
çšïŒæ°Žã«æº¶ãããïŒml溶液ãšããåçµä¹Ÿç¥ãã
ããåæ§ã«ã㊠âã·ã¹ãã€ã³90mgïŒ0.75ããªã¢ã«ïŒåã³ïŒ€â
ãã³ããã140.0mg䞊ã³ã« âã·ã¹ãã€ã³180mgïŒ1.5ããªã¢ã«ïŒïŒãã³ã
ããæ·»å ãªãïŒã ãå«æããã·ã¹ãã€ã³ã®åçµä¹Ÿç¥ã補é ããã 泚å°æº¶æ¶²ã®è£œé ã®ããã«ã¯äŸïŒåã³äŸïŒã«ãã
ã¢ã³ãã«ç¶ã®å 容ç©ãããããïŒæ³šå°çšïŒæ°ŽïŒml
äžã«æº¶è§£ããã äŸ ïŒ äœçšç©è³ªãšããŠâã·ã¯ãããã·ã«ã¢ãã³å¡©â82
mgïŒïŒ0.15ããªã¢ã«ïŒåã³ç©è³ªâã·ã¯ãããã·ã«
ã¢ãã³å¡©âã«å¯Ÿãçš®ã ã®ã¢ã«æ¯ïŒïŒåãïŒååã³
10åïŒã§ïŒ¬âã·ã¹ãã€ã³ã次ã®ããã«å«æããçµ
ã¿åãã調å€ïŒ ã·ã¯ãããã·ã«ã¢ãã³å¡©ïŒïŒâãïŒâïŒãã¹â
ïŒïŒâã¯ãã«ãšãã«ïŒâã¢ããâïŒâãªããœâãã
ã©ãããâ2HâïŒïŒïŒïŒïŒâãªããµã¶ãã¹ããª
ã³âïŒâã€ã«âããªãâïŒâã¡ã«ã«ããâããã
ã³ã¹ã«ãã³é žâã·ã¯ãããã·ã«ã¢ãã³å¡©ã ïŒ æ³šå°ç¶ã¯æ¬¡ã®ãã®ãå«æããïŒ
ãè¡šã
ç©è³ªâã·ã¯ãããã·ã«ã¢ãã³å¡©âãâã·ã¹ã
ã€ã³åã³å Žåã«ããå¿ èŠã§ããã°ãâãã³ãã
ããçªçŽ ãå¹ã蟌ã¿ãªãããæ°Žã«æº¶ãããïŒml容
éã®æº¶æ¶²ãã€ãããå ¬ç¥æ³ã§æ» èæ¿Ÿéããã次ã
ã§ããã®æº¶æ¶²ãç¡èæ¡ä»¶äžã«åçµä¹Ÿç¥çšæ ãæã
ã10mlè€è²æ³šå°ç¶ã«é éããåçµä¹Ÿç¥è£ 眮äžã§å
çµä¹Ÿç¥ãããåŒãç¶ããåçµä¹Ÿç¥è£ 眮ã«ä¹Ÿç¥çªçŽ
ãéããã¢ã³ãã«ç¶ãè£ çœ®äžã§å¯éããã æäžå¯èœãªæ³šå°æº¶æ¶²ã®è£œé ã®ããã«ã¢ã³ãã«ç¶
ã®å 容ç©ã泚å°çšæ°ŽïŒmläžã«æº¶ããã ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããªã³ãšããª
ååç©ãåé¢ããŠäœ¿çšããããã®èª¿å€ äŸ ïŒ äŸ ïŒã«èšèŒããããã«âã·ã¯ãããã·ã«ã¢ãã³
å¡©â82mgïŒ0.15ããªã¢ã«ïŒåã³ïŒ€âãã³ããã
250.0mgãïŒæ³šå°çšïŒæ°Žäžã«æº¶ããã容éïŒmlãš
ããåçµä¹Ÿç¥ãããã äŸ ïŒ äŸïŒã«èšèŒããããã«ã·ã¹ãã€ã³36.0mgïŒ0.3
ããªã¢ã«ïŒåã³ïŒ€âãã³ããã220.0mgãïŒæ³šå°
çšïŒæ°Žã«æº¶ãããïŒml溶液ãšããåçµä¹Ÿç¥ãã
ããåæ§ã«ã㊠âã·ã¹ãã€ã³90mgïŒ0.75ããªã¢ã«ïŒåã³ïŒ€â
ãã³ããã140.0mg䞊ã³ã« âã·ã¹ãã€ã³180mgïŒ1.5ããªã¢ã«ïŒïŒãã³ã
ããæ·»å ãªãïŒã ãå«æããã·ã¹ãã€ã³ã®åçµä¹Ÿç¥ç©ã補é ããã 泚å°æº¶æ¶²ã®è£œé ã®ããã«ã¯äŸïŒåã³äŸïŒã«ãã
ã¢ã³ãã«ç¶ã®å 容ç©ãããããïŒæ³šå°çšïŒæ°ŽïŒml
äžã«æº¶è§£ããã 補é äŸ ïŒ ïŒâïŒïŒâã¯ãã«âãšãã«ã¢ããïŒâïŒâïŒïŒâ
ã¯ãã«âãšãã«ïŒâïŒâïŒïŒâããããã·âãšãã«
ããªïŒâããã©ãããâ2HâïŒïŒïŒïŒïŒâãªããµ
ã¶ãã¹ããªã³âïŒâãªãã·ã ïŒâããããã·ãã¹ãã¢ãã5.4gïŒ19ããªã¢ã«ïŒ
ãå¡©åã¡ãã¬ã³40mläžã«æžæ¿ãããïŒâã¡ã«ã«ã
ããšã¿ãâã«2.8mlïŒ39ããªã¢ã«ïŒãæ··åããïŒ
âã«å·åŽããæªæäžã«ããªã¯ãã«é ¢é ž150mlãå
ããïŒæ¥åŸã«ïŒâã§æ¿çž®ããæ²¹ç¶ç©è³ªãã·ãªã«ã²
ã«äžæº¶é¢å€ã¯ãããã«ã ïŒã¡ã¿ãâã«ïŒ15ïŒïŒïŒ
åã³ã¢ã»ãã³ïŒå¡©åã¡ãã¬ã³ïŒïŒïŒïŒïŒãçšããŠ
é補ããã å éïŒ3.4gïŒçè«å€ã®53ïŒ ïŒ Rfâå€ïŒ0.45 å±éå€ ïŒã¯ãããã«ã ïŒã¡ã¿ãâã«ïŒ5.1ïŒ ç è²ïŒæ² çŽ è£œé äŸ ïŒ ïŒâïŒãã¹âïŒïŒâã¯ãã«âãšãã«ã¢ããâïŒâ
ãïŒâããããã·âïŒâã¡ã«ã«ããâãããã«â
(1)âããªãâããã©ãããâ2HâïŒïŒïŒïŒïŒâãª
ããµã¶ãã¹ããªã³âïŒâãªãã·ã ïŒâããããã·âã·ã¯ããã¹ãã¢ããã«ã¢ã»ã
ã³äžïŒâã§ïŒïŒïŒâã¡ã«ã«ããâïŒâããããâ
ã«ïŒåéãå ãããïŒæéåŸãã¢ã»ãã³ãæ°Žæµã
ã³ãã«ããç空äžã§æ°·æµŽäžã§å·åŽäžã«çå»ããã
æ®åãæ¡åçšèå±€ã¯ãããã°ã©ã ã«ããã·ãªã«ã²
ã«ãã¬âãäžé ¢é žãšã¹ãã«ïŒã¢ã»ãã³ïŒïŒïŒïŒïŒ
ã济é¢å€ãšããŠåé¢ãããRfïŒ0.4ïŒã¢ã«ãã«å
掻æ§ïŒÎ³âããããã³ãžã«ããªãžã³ïŒåã³ããªåº
äžã®æ²çŽ âé žã®æ€åºãRfïŒ0.4ã®åž¯åãå¡©åã¡ã
ã¬ã³ã§å·ææœåºãããžãšãã«ãšâãã«ã§ã®æåºã«
ãã埮现æ¶ã®ç²çæç©ãåŸããããèç¹ïŒè£æ£ãª
ãïŒïŒ90ã95âã
ã€ã³åã³å Žåã«ããå¿ èŠã§ããã°ãâãã³ãã
ããçªçŽ ãå¹ã蟌ã¿ãªãããæ°Žã«æº¶ãããïŒml容
éã®æº¶æ¶²ãã€ãããå ¬ç¥æ³ã§æ» èæ¿Ÿéããã次ã
ã§ããã®æº¶æ¶²ãç¡èæ¡ä»¶äžã«åçµä¹Ÿç¥çšæ ãæã
ã10mlè€è²æ³šå°ç¶ã«é éããåçµä¹Ÿç¥è£ 眮äžã§å
çµä¹Ÿç¥ãããåŒãç¶ããåçµä¹Ÿç¥è£ 眮ã«ä¹Ÿç¥çªçŽ
ãéããã¢ã³ãã«ç¶ãè£ çœ®äžã§å¯éããã æäžå¯èœãªæ³šå°æº¶æ¶²ã®è£œé ã®ããã«ã¢ã³ãã«ç¶
ã®å 容ç©ã泚å°çšæ°ŽïŒmläžã«æº¶ããã ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããªã³ãšããª
ååç©ãåé¢ããŠäœ¿çšããããã®èª¿å€ äŸ ïŒ äŸ ïŒã«èšèŒããããã«âã·ã¯ãããã·ã«ã¢ãã³
å¡©â82mgïŒ0.15ããªã¢ã«ïŒåã³ïŒ€âãã³ããã
250.0mgãïŒæ³šå°çšïŒæ°Žäžã«æº¶ããã容éïŒmlãš
ããåçµä¹Ÿç¥ãããã äŸ ïŒ äŸïŒã«èšèŒããããã«ã·ã¹ãã€ã³36.0mgïŒ0.3
ããªã¢ã«ïŒåã³ïŒ€âãã³ããã220.0mgãïŒæ³šå°
çšïŒæ°Žã«æº¶ãããïŒml溶液ãšããåçµä¹Ÿç¥ãã
ããåæ§ã«ã㊠âã·ã¹ãã€ã³90mgïŒ0.75ããªã¢ã«ïŒåã³ïŒ€â
ãã³ããã140.0mg䞊ã³ã« âã·ã¹ãã€ã³180mgïŒ1.5ããªã¢ã«ïŒïŒãã³ã
ããæ·»å ãªãïŒã ãå«æããã·ã¹ãã€ã³ã®åçµä¹Ÿç¥ç©ã補é ããã 泚å°æº¶æ¶²ã®è£œé ã®ããã«ã¯äŸïŒåã³äŸïŒã«ãã
ã¢ã³ãã«ç¶ã®å 容ç©ãããããïŒæ³šå°çšïŒæ°ŽïŒml
äžã«æº¶è§£ããã 補é äŸ ïŒ ïŒâïŒïŒâã¯ãã«âãšãã«ã¢ããïŒâïŒâïŒïŒâ
ã¯ãã«âãšãã«ïŒâïŒâïŒïŒâããããã·âãšãã«
ããªïŒâããã©ãããâ2HâïŒïŒïŒïŒïŒâãªããµ
ã¶ãã¹ããªã³âïŒâãªãã·ã ïŒâããããã·ãã¹ãã¢ãã5.4gïŒ19ããªã¢ã«ïŒ
ãå¡©åã¡ãã¬ã³40mläžã«æžæ¿ãããïŒâã¡ã«ã«ã
ããšã¿ãâã«2.8mlïŒ39ããªã¢ã«ïŒãæ··åããïŒ
âã«å·åŽããæªæäžã«ããªã¯ãã«é ¢é ž150mlãå
ããïŒæ¥åŸã«ïŒâã§æ¿çž®ããæ²¹ç¶ç©è³ªãã·ãªã«ã²
ã«äžæº¶é¢å€ã¯ãããã«ã ïŒã¡ã¿ãâã«ïŒ15ïŒïŒïŒ
åã³ã¢ã»ãã³ïŒå¡©åã¡ãã¬ã³ïŒïŒïŒïŒïŒãçšããŠ
é補ããã å éïŒ3.4gïŒçè«å€ã®53ïŒ ïŒ Rfâå€ïŒ0.45 å±éå€ ïŒã¯ãããã«ã ïŒã¡ã¿ãâã«ïŒ5.1ïŒ ç è²ïŒæ² çŽ è£œé äŸ ïŒ ïŒâïŒãã¹âïŒïŒâã¯ãã«âãšãã«ã¢ããâïŒâ
ãïŒâããããã·âïŒâã¡ã«ã«ããâãããã«â
(1)âããªãâããã©ãããâ2HâïŒïŒïŒïŒïŒâãª
ããµã¶ãã¹ããªã³âïŒâãªãã·ã ïŒâããããã·âã·ã¯ããã¹ãã¢ããã«ã¢ã»ã
ã³äžïŒâã§ïŒïŒïŒâã¡ã«ã«ããâïŒâããããâ
ã«ïŒåéãå ãããïŒæéåŸãã¢ã»ãã³ãæ°Žæµã
ã³ãã«ããç空äžã§æ°·æµŽäžã§å·åŽäžã«çå»ããã
æ®åãæ¡åçšèå±€ã¯ãããã°ã©ã ã«ããã·ãªã«ã²
ã«ãã¬âãäžé ¢é žãšã¹ãã«ïŒã¢ã»ãã³ïŒïŒïŒïŒïŒ
ã济é¢å€ãšããŠåé¢ãããRfïŒ0.4ïŒã¢ã«ãã«å
掻æ§ïŒÎ³âããããã³ãžã«ããªãžã³ïŒåã³ããªåº
äžã®æ²çŽ âé žã®æ€åºãRfïŒ0.4ã®åž¯åãå¡©åã¡ã
ã¬ã³ã§å·ææœåºãããžãšãã«ãšâãã«ã§ã®æåºã«
ãã埮现æ¶ã®ç²çæç©ãåŸããããèç¹ïŒè£æ£ãª
ãïŒïŒ90ã95âã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ äžè¬åŒ ãåŒäžãR1ãR2åã³R3ã¯åäžåã¯ç°ãªã€ãŠã
ãŠãããæ°ŽçŽ ãã¡ãã«ããšãã«åã¯ïŒâã¯ãã«ãš
ãã«åºãè¡šããããã€ããã§ãããã®åºã®å°ãªã
ãšãïŒã€ã¯ïŒâã¯ãã«ãšãã«åºãè¡šãããR4ã¯
æ°ŽçŽ ãè¡šãããR5ã¯C2ãC6âããããã·âã¢ã«
ãã«åºåã¯C2ãC6âã¡ã«ã«ããã¢ã«ãã«åºãè¡š
ããããã®éãããã®åºã®ãããããä»å çã«ã¡
ã«ã«ããåºãæããŠããŠãããåã¯R5ã¯ã«ã«ã
âC1ãC6âã¢ã«ã³ãã·âC1ãC10âã¢ã«ãã«åºã
ïŒâã¢ããâïŒâã«ã«ãâC1ãC6âã¢ã«ã³ãã·
âãšãã«åºâïŒãC2ãC6âã¢ã«ã«ãã€ã«ã¢ãã
âïŒâã«ã«ãâC1ãC6âã¢ã«ã³ãã·âãšãã«åºã
C2ãC6âã¹ã«ãã¢ã«ãã«åºåã¯ã¡ã«ã«ããåºã
æããŠããC2ãC6âã¹ã«ãã¢ã«ãã«åºãè¡šããã
ã®ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ããªã³åã¯è©²å
åç©ã®ççåŠçã«èªå®¹æ§ã®å¡©ãšäžè¬åŒ R6SR7 ãåŒäžãR6ã¯ããããã·åºãã¡ã«ã«ããåºã
ã¢ããåºãC2ãC6âã¢ã«ã«ãã€ã«ã¢ããåºãã¹
ã«ãåºãã«ã«ãâC1ãC6âã¢ã«ã³ãã·åºåã¯ã«
ã«ããã·åºããéžæããã眮æåïŒååã¯ïŒåã§
眮æãããŠããçŽéåã¯åæéã®C2ãC6âã¢ã«
ãã«åºãè¡šãããR7ã¯æ°ŽçŽ ãè¡šããããR6ãC2
ãC6âã¹ã«ãã¢ã«ãã«åºãè¡šããå ŽåãR7ã¯C2
ãC6âã¹ã«ãã¢ã«ãã«ããªåºã§ãã€ãŠãããã®
ããªååç©åã¯è©²ååç©ã®ççåŠçã«èªå®¹æ§ã®å¡©
ãšãçµã¿åãããŠãªãããšãç¹åŸŽãšããæçå€ã ïŒ äžè¬åŒã®ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ã
ãªã³åã¯è©²ååç©ã®ççåŠçã«èªå®¹æ§ã®å¡©å°ãªã
ãšãïŒçš®åã³äžè¬åŒã®ããªååç©åã¯è©²ååç©
ã®ççåŠçã«èªå®¹æ§ã®å¡©å°ãªããšãïŒçš®ãå«æã
ãç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®è¬å€ã ïŒ äžè¬åŒã®ïŒâã¹ã«ãã€ãâãªããµã¶ãã¹ã
ãªã³ã®éã0.5ã3500mgã§ãããäžè¬åŒã®ããª
ååç©ã®éã䜿çšããïŒâã¹ã«ãã€ãâãªããµã¶
ãã¹ããªã³ã®ïŒã¢ã«ããã0.2ã10ã¢ã«ïŒmgïŒã§
ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®è¬å€ã ïŒ äœçšç©è³ªãšããŠäžè¬åŒã®ïŒâã¹ã«ãã€ãâ
ãªããµã¶ãã¹ããªã³åã¯ãã®ççåŠçã«èªå®¹æ§ã®
å¡©å°ãªããšãïŒçš®åã³äžè¬åŒã®ããªååç©åã¯
ãã®ççåŠçã«èªå®¹æ§ã®å¡©å°ãªããšãïŒçš®ãåžžçš
ã®å»è¬æ æå€åã³ïŒåã¯åžéå€ãšäžç·ã«å«æãã
ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé åã¯ç¬¬ïŒé èšèŒã®è¬å€ã ïŒ ïŒåã®å¥åã®ã ïœïŒ å°ãªããšãäžè¬åŒã®ïŒâã¹ã«ãã€ãâãª
ããµã¶ãã¹ããªã³åã¯è©²ååç©ã®ççåŠçã«èª
容æ§ã®å¡©åç¬ã§åã¯åžžçšã®å»è¬æ æå€åã³ïŒå
ã¯åžéå€ãšäžç·ã«æããã¬âã¬ã³åŒè£œå€åã³ ïœïŒ å°ãªããšãäžè¬åŒã®ããªååç©åã¯è©²å
åç©ã®ççåŠçã«èªå®¹æ§ã®å¡©åç¬ã§åã¯åžžçšã®
å»è¬æ æå€åã³ïŒåã¯åžéå€ãšäžç·ã«æããã¬
âã¬ã³åŒè£œå€ã«åããããŠããæ²»ççšããã±â
ãžã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®è¬å€ã ïŒ å°ãªããšãïŒçš®ã®äžè¬åŒã®ïŒâã¹ã«ãã€ã
âãªããµã¶ãã¹ããªã³åã¯ççåŠçã«èªå®¹æ§ã®å¡©
åã³å°ãªããšãïŒçš®ã®äžè¬åŒã®ããªååç©åã¯
ççåŠçã«èªå®¹æ§ã«å¡©ãäžç·ã«åã¯å¥ã ã«åžžçšã®
å»è¬æ æå€ãããã¯åžéå€ãšå ±ã«å å·¥ããŠå»è¬èª¿
å€åœ¢ãšããããšã«ãã補é ãããŠããç¹èš±è«æ±ã®
ç¯å²ç¬¬ïŒé ãã第ïŒé ãŸã§ã®ããããïŒé èšèŒã®
è¬å€ã ïŒ äžè¬åŒãäžè¬åŒâ² R6SR7 åŒäžãR6ã¯ã°ã«ã¿ããªãã«åºã§ãããåã¯
ããããã·åºãã¡ã«ã«ããåºãã¢ããåºãã¢ã»ã
ã«ã¢ããåºãã¹ã«ãåºãã«ã«ãâC1ãC6âã¢ã«
ã³ãã·åºåã¯ã«ã«ããã·åºããéžæããã眮æå
ïŒååã¯ïŒåã§çœ®æãããŠããçŽéåã¯åæéã®
C2ãC6âã¢ã«ãã«åºãè¡šãããR7ã¯æ°ŽçŽ ãè¡šã
ãããR6ãC2ãC6âã¹ã«ãã¢ã«ãã«åºãè¡šãã
å ŽåãR7ã¯C2ãC6âã¹ã«ãã¢ã«ãã«ããªåºã§ã
ã€ãŠããã®ããªååç©ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬
ïŒé èšèŒã®è¬å€ã ïŒ äžè¬åŒâ²ã®ååç©å°ãªããšãïŒçš®ãåžžçšã®
å»è¬æ æå€åã³ïŒåã¯åžéå€ãšå ±ã«å«æããç¹èš±
è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®è¬å€ã ïŒ äžè¬åŒâ²ã®ååç©ã®å«éã0.1mgã25gã§ã
ãç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé åã¯ç¬¬ïŒé èšèŒã®è¬å€ã ïŒïŒ äžè¬åŒâ²ã®ããªååç©ãåžžçšã®å»è¬æ æ
å€ãããã¯åžéå€ãšå ±ã«å»è¬èª¿å€åœ¢ã«å å·¥ããã
ãšã«ãã補é ãããŠããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã
ã第ïŒé ãŸã§ã®ããããïŒé èšèŒã®è¬å€ã
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3151977 | 1981-12-31 | ||
| DE3151977.6 | 1981-12-31 | ||
| DE3222006.5 | 1982-06-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58118595A JPS58118595A (ja) | 1983-07-14 |
| JPH0373525B2 true JPH0373525B2 (ja) | 1991-11-22 |
Family
ID=6150044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP22783682A Granted JPS58118595A (ja) | 1981-12-31 | 1982-12-28 | ïŒâã¹ã«ãã£ãâãªããµã¶ãã¹ããªã³ãå«æããæçå€ |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS58118595A (ja) |
-
1982
- 1982-12-28 JP JP22783682A patent/JPS58118595A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS58118595A (ja) | 1983-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019261702B2 (en) | Processes For Preparing Oxathiazin-Like Compounds | |
| WO2018028494A1 (zh) | å西ä»æ»šProTideä¹æ°§æŽ»ååè¯åå ¶åºçš | |
| JP4500672B2 (ja) | æççãæãŠã€ã«ã¹ããã³æè¡æ ç掻æ§ãæãããã³ãŸã€ãœã»ã¬ã³ã¢ãŸãŒã«èªå°äœãªãã³ã«ãããã®äœ¿çš | |
| PT679656E (pt) | Melhoramentos em complexos de platina | |
| US4623742A (en) | Oxazaphosphorin-4-thio-alkanesulphonic acids, and neutral salts thereof | |
| WO2021127482A1 (en) | Synthesis of compounds to promote hair growth | |
| WO2016130271A1 (en) | Substituted pyrrolo[2,3-d]pyrimidines for selectively targeting tumor cells with fr-alpha and fr-beta type receptors | |
| US4770870A (en) | Method for reducing pain associated with the administration of 4-sulfido-oxazaphosphorines and 4-sulfoalkylthio-oxazaphorphorines | |
| JPS6016934A (ja) | æè «çå€ | |
| ES2703740T3 (es) | Compuestos de organoarsénico y procedimientos para el tratamiento del cáncer | |
| EA016838B1 (ru) | СпПÑÐŸÐ±Ñ Ð»ÐµÑÐµÐœÐžÑ Ñака О ÐŽÑÑÐ³ÐžÑ Ð·Ð°Ð±ÐŸÐ»ÐµÐ²Ð°ÐœÐžÐ¹ ОлО паÑПлПгОÑеÑÐºÐžÑ ÑПÑÑПÑМОй Ñ Ð¿ÑОЌеМеМОеЌ клевÑЎОМа (lfmau) О ÑелбОвÑЎОМа (ldt) | |
| CN116444408A (zh) | äžç§å€é¶ç¹ååç¡«ä»è¡çç©ãè¯ç©ç»åç©åå ¶æè¿ç€åºçš | |
| CN117700419B (zh) | äžæ°§åæ°®äŸäœåååè¡çç©åå ¶åšæ²»çè¿ç€çŸç äžççšé | |
| CN101395166B (zh) | çšäºæ²»ççççååç©åæ¹æ³ | |
| US7732485B2 (en) | Treatment of cancer | |
| CN108101943A (zh) | äžç§æ¿è¯ºçŠéŠåè¯æå¯è¯çšçåå ¶åšå»è¯äžçåºçš | |
| PT1607399E (pt) | Bis-(n,n'-bis-(2-haloetil)amino)fosforamidatos como agentes antitumorais | |
| WO2008076826A1 (en) | Pyrophosphoramide alkylators | |
| NL8220420A (nl) | Farmaceutische samenstelling, die antitumoractiviteit bezit. | |
| JPS58118595A (ja) | ïŒâã¹ã«ãã£ãâãªããµã¶ãã¹ããªã³ãå«æããæçå€ | |
| JP2026509276A (ja) | ïŒïŒïŒã·ã¹ïŒã¬ããã€ã³é žåã³ã¢ã¹ã³ã«ãã³é žãå«ãã³ã³ãžã¥ã²ãŒãååç© | |
| Borisov | Soviet antitumor preparations | |
| CN105899486A (zh) | çšäºæ²»ççççååç©åæ¹æ³ | |
| DE3247436A1 (de) | 4-sulfido-oxazaphosphorine und deren verwendung bei der krebsbekaempfung und zur immunsuppression | |
| HK1240209A1 (en) | Processes for preparing oxathiazin-like compounds |